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SUMMARY 
The present work focuses on two autosomal recessive inborn errors of metabolism, 3-
methylcrotonyl-CoA carboxylase (MCC) deficiency, a defect in the catabolism of leucine, and 
on the cblD defect of intracellular vitamin B12 (cobalamin) metabolism. 
MCC is a heteromeric mitochondrial enzyme composed of biotin-containing α (MCCA) and 
smaller β (MCCB) subunits encoded by MCCA and MCCB, respectively. We report studies of 
the c.1054G→A mutation in exon 11 of MCCB detected in the homozygous state in a patient 
with MCC deficiency. Sequence analysis of MCCB cDNA revealed two overlapping 
transcripts, one containing the normal 73 bp of exon 11 including the missense mutation 
c.1054G→A (p.G352R), the other with exon 11 replaced by a 64 bp sequence from intron 10 
(cryptic exon) that maintains the reading frame and is flanked by acceptable splice 
consensus sites. In expression studies, we show that both transcripts lack detectable MCC 
activity. Western blot analysis showed slightly reduced levels of MCCB using the transcript 
containing the missense mutation, whereas no MCCB was detected with the transcript 
containing the cryptic exon. Analysis of the region harboring the mutation revealed that the 
c.1054G→A mutation is located in an exon splice enhancer sequence. Using MCCB 
minigene constructs to transfect MCCB-deficient fibroblasts, we demonstrate that the 
reduction in utilization of exon 11 associated with the c.1054G→A mutation is due to 
alteration of this exon splice enhancer. Further, we show that optimization of the weak splice 
donor site of exon 11 corrects the splicing defect. To our knowledge, this is the first 
demonstration of a point mutation disrupting an exon splice enhancer that causes exon 
skipping along with utilization of a cryptic exon. 
In man, cobalamin is an essential cofactor in only two metabolic pathways. Intracellular 
conversion of cobalamin to its two coenzymes, adenosylcobalamin (AdoCbl) in mitochondria 
and methylcobalamin (MeCbl) in the cytoplasm, is necessary for the homeostasis of 
methylmalonic acid and homocysteine. We have identified the MMADHC gene responsible 
for the cblD defect that can cause isolated methylmalonic aciduria, isolated homocystinuria, 
or both. Various mutations are associated with each of the three biochemical phenotypes of 
the disorder. Using expression vectors containing the wildtype MMADHC with an enhanced 
mitochondrial leader sequence, mutations changing possible downstream sites of reinitiation 
or mutations introducing stop codons, we provide evidence that reinitiation of translation at 
downstream AUGs explains most of the phenotypes found in cblD patients. Furthermore, our 
data indicate that the sequence after Met116 is sufficient for MeCbl synthesis whereas the 
sequence between Met62 and Met116 is required for AdoCbl synthesis. Our findings support 
the hypothesis that a delicate balance exists between cytosolic MeCbl and mitochondrial 
AdoCbl synthesis, supporting the role of the MMADHC protein as a branching point in 
intracellular cobalamin trafficking.  
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ZUSAMMENFASSUNG 
Die vorliegende Arbeit beschäftigt sich mit zwei autosomal rezessiv vererbten 
Stoffwechselkrankheiten, dem 3-Methylcrotonyl-CoA Carboxylase (MCC) Mangel, welches 
ein Defekt im Leuzin-Abbau ist, und dem cblD Defekt, einer Störung des intrazellulären 
Vitamin B12 (Cobalamin) Stoffwechsels. 
MCC ist ein heteromeres mitochondriales Enzym aus Biotin-bindenden α (MCCA) und 
kleineren β (MCCB) Untereinheiten, welche durch MCCA und MCCB kodiert sind. Wir 
berichten über die Mutation c.1054G>A (p.G352R) in Exon 11 von MCCB, welche wir 
homozygot bei einem MCC-Patienten gefunden haben. Die Analyse der cDNA Sequenz von 
MCCB ergab zwei überlappende Transkripte: eines mit der Mutation c.1054G>A, sowie ein 
weiteres mit Ersatz der 73 bp von Exon 11 durch 64 bp aus Intron 10. Dieses kryptische 
Exon verändert das Leseraster nicht und weist akzeptable Spleiss-Stellen auf. 
Expressionsstudien zeigen, dass beide Transkripte keine MCC Aktivität besitzen bei nur 
reduzierter Proteinmenge beim mutationstragenden Transkript sowie Proteinverlust des 
Transkriptes mit kryptischem Exon. Die Mutation c.1054G>A ist Teil eines Exon-Spleiss-
Enhancers. Transfektionsexperimente von MCCB Minigen Konstrukten in MCCB defizienten 
Fibroblasten zeigten bei Veränderung des Exon-Spleiss-Enhancers ein vermindertes 
Spleissen von Exon 11. Zudem konnte bei Sequenz-Optimierung der Exon 11-Spleiss-
Stellen der Spleiss-Defekt korrigiert werden. Unseres Wissens ist dies der erste Nachweis 
eines durch Punktmutation in einem Exon-Spleiss-Enhancer resultierenden Exonverlustes 
bei gleichzeitiger Insertion eines kryptischen Exons. 
Beim Menschen wird Cobalamin für nur zwei Reaktionsschritte des Stoffwechsels benötigt: 
als mitochondriales Adenosylcobalamin (AdoCbl) für den Abbau von Methylmalonsäure und 
als zytosolisches Methylcobalamin (MeCbl) für die Methylierung von Homocystein. Bei 
Vorliegen eines cblD-Defektes besteht eine Methylmalonazidurie, eine 
Hyperhomocysteinämie oder eine Kombination aus beiden Symptomen. Uns gelang die 
Klonierung des MMADHC Gens, welches für den cblD Defekt verantwortlich ist. 
Verschiedene Mutationen sind mit den drei Phänotypen des cblD-Defektes assoziiert. Durch 
Veränderung der mitochondrialen Importsequenz, durch Korrektur der zusätzlichen AUGs 
(Transkriptions-Start) und durch Einfügen weiterer Stop-Mutationen konnte gezeigt werden, 
dass eine Reinitiation der Transkription an weiteren AUGs die in cblD Patienten gefundenen 
Phänotypen erklären könnte. Weiter haben wir Hinweise darauf, dass ein cblD-Protein mit 
Beginn bei Met116 weiter MeCbl synthetisieren kann, und dass die Sequenz zwischen Met62 
und Met116 notwendig für die Synthese von AdoCbl ist. Unsere Resultate bestätigen die 
Hypothese eines kritischen Gleichgewichts zwischen zytosolischer MeCbl und 
mitochondrialer AdoCbl Synthese. Das MMADHC Protein spielt somit eine wichtige Rolle bei 
der intrazellulären Cobalamin Verteilung. 
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1 Inborn Errors of Metabolism 
The term “inborn error of metabolism” (IEM) was first used in 1908 by a British physician, Sir 
Archibald Garrod (1857 - 1936) while describing the nature and mode of inheritance of 
alkaptonuria, a disease in the metabolism of phenylalanine and tyrosine (1). 
To date more than 500 IEMs are known (2). They occur relatively frequently (1:1'000 to 
1:3'000 affected infants (3)) and, as a disease entity, are of considerable public health 
significance (2, 4). If undiagnosed and untreated, they can cause, depending on the 
corresponding disease, irreversible mental retardation, physical disability, neurological 
damage and fatality. For many IEMs, the lack of correlation between phenotype and 
genotype is one of many unresolved problems. 
Consider a reaction converting substrate A to product B (1): In most IEMs, the problems 
arise due to 1) accumulation of the substrate (2), 2) the reduced availability of the product 
(3), 3) the production of another toxic metabolite C (4), or 4) a combination of 2-4 (Figure 1). 
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Figure 1: A schematic view of the most common problems arising from inborn errors of metabolism. If the 
conversion of A to B (1) is defective, problems can arise either due to the accumulation of A (2), the lack of B (3) 
or the production of another toxic metabolite C (4) or a combination of 2-4. 
 
IEMs can be classified according to the type of metabolism involved: 
 
1.1 Amino acid disorders 
Amino acid disorders (amino acidopathies) are caused by defective catabolic pathways of 
amino acids. If there is an abnormal accumulation of amino acids in the plasma or an 
abnormal excretion of amino acids in the urine, the disorder is called either an “amino 
acidemia” or an “amino aciduria” depending on the major metabolite found. The symptoms of 
amino acid disorders typically result from an accumulation of the substance that cannot be 
metabolized. Often amino acid disorders present in initially well newborns that become 
acutely symptomatic after catabolic stress due to fasting or intercurrent infection or after a 
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change to a more protein rich feeding. Symptoms can include metabolic decompensation 
with lethargy and poor appetite and may progress to encephalopathy, coma and death, 
provided they are not recognized and treated promptly. Examples are maple syrup urine 
disease (MSUD, Mendelian Inheritance in Man (MIM) 248600) or tyrosinemia type 1. Other 
amino acidemias such as phenylketonuria do not present with acute symptoms but may lead 
to chronic progressive brain damage if they are not detected in the newborn period and 
treated promptly.  
 
1.2 Organic acidemias  
Organic acidemias (organic acidurias) are defined by an accumulation of abnormal acyl-CoA 
derivatives, which are usually toxic, as well as increased excretion of organic acids in the 
urine (5). Affected children develop life-threatening episodes of metabolic decompensation, 
poor feeding, vomiting and lethargy after an initial period of well-being. Later in life affected 
individuals may present with developmental delay or regression. 
Examples of organic acidemias include methylmalonic acidemia (MMA, MIM 251000 and 
others) and propionic acidemia (PA, MIM 606054). For more detailed information on organic 
acidurias see section 2. 
 
1.3 Urea cycle disorders 
Urea cycle disorders are defects in the metabolic pathways transforming waste nitrogen into 
non toxic urea which can be easily secreted in the urine. Similar to amino acidopathies and 
organic acidemias these disorders often present in initially well newborns that become 
hyperammonemic after catabolic stress due to fasting or intercurrent infection or after a 
change to more protein rich feeding. As ammonia levels increase, infants quickly develop 
vomiting, hypothermia, irritability, lethargy, seizures and cerebral edema. Without 
intervention, they become comatose and die. 
Examples of urea cycle disorders include citrullinemia (MIM 215700) and ornithine 
transcarbamylase deficiency (MIM 311250). 
 
1.4 Carbohydrate disorders 
Carbohydrate disorders are caused by defects in any of the pathways involved in the 
metabolism of carbohydrates. Affected children may present with lethargy and seizures due 
to hypoglycemia during times of fasting or with acute hypoglycemia leading to confusion, 
disorientation, coma and death (6). In other cases, these disorders can also lead to acute 
liver dysfunction, to chronic liver damage or to cardiomyopathy. 
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Examples of carbohydrate disorders include galactosemia (MIM 230400) and glycogen 
storage diseases like for example van Gierke disease (glycogen storage disorder type 1, 
MIM 232200). 
 
1.5 Mitochondrial disorders 
One of the hallmarks of mitochondrial disorders is elevated lactic acid which is usually 
increased due to a defect in either the tricarboxylic acid (TCA) cycle or oxidative 
phosphorylation in the respiratory chain. As many mitochondrial disorders have remained 
undiagnosed, the frequency by which they are now recognized increases (7).  
The disorders can affect solely muscle, muscle and brain or multiple organs. Examples are 
pyruvate dehydrogenase deficiency, cytochrome C oxidase deficiency (MIM 220110) or 
deficiency of any other complex of the respiratory chain, mitochondrial DNA depletion 
syndrome, and many more. 
 
1.6 Mitochondrial fatty acid oxidation disorders 
Mitochondrial fatty acid oxidation plays an important role in the production of energy, 
especially during times of fasting (8): organic and fatty acids as well as amino acids are 
metabolized to acetyl-CoA within mitochondria. A condensation reaction with oxaloacetate 
then forms citric acid which is further oxidized in the TCA cycle. During times of low 
carbohydrate intake or fasting, affected children present with hypoglycemia, encephalopathy 
and lethargy. Cardiomyopathy and cardiac arrhythmias may also be present. Other findings 
may include hyperammonemia, metabolic acidosis. Examples include medium chain acyl-
CoA dehydrogenase deficiency (MIM 201450), carnitine palmitoyltransferase deficiencies 
(MIM 255120, 600650) and mitochondrial trifunctional protein deficiency (MIM 600890). 
 
1.7 Peroxisomal disorders 
Peroxisomal disorders are characterized by a defect in one of the many functions carried out 
in peroxisomes. These include beta-oxidation of very long-chain fatty acids, the oxidation of 
dicarboxylic acids and bile acids, and the degradation of hydrogen peroxide by catalase. 
Clinical symptoms of peroxisomal dysfunction include dysmorphic facial features, 
microcephaly, hypotonia and sometimes neurological dysfunction. An example is Zellweger 
syndrome (MIM 214100). 
 
1.8 Lysosomal storage disorders 
Lysosomal storage disorders include defects in lysosomal degradation pathways of various 
compounds like glycoproteins, mucopolysaccharides and sphingolipids. Deficiency of a 
lysosomal enzyme leads to accumulation of partially degraded substrates. Thus the 
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lysosomes increase in size and are incapable of exerting their cellular function. The location 
and the extent of the occurring storage greatly influences the clinical manifestations. 
Symptoms may include progressive hepatomegaly, splenomegaly, short stature, neurological 
regression and many more (9). Examples include mucopolysaccharidoses, e.g. Hurler 
syndrome (MIM 607014) or sphingolipidoses, e.g. Fabry disease (MIM 301500), Gaucher 
disease (MIM 231000) and Krabbe disease (MIM 245200). 
 
1.9 Others 
Other classes of inborn errors of metabolism include purine and pyrimidine disorders, 
congenital disorders of glycosylation, porphyrias, steroid metabolism disorders and metal 
metabolism disorders. 
 
1.10 Pathogenesis of inborn errors of metabolism 
The pathogenesis of an IEM can generally be attributed to the loss- or gain-of-function of 
mutant proteins (usually an enzyme or a transporter). The genetic basis of IEMs is extremely 
heterogeneous and can involve any type of genetic defect. The disease is generally 
associated with altered metabolite flux through the pathway in which the mutant protein is 
involved. Importantly, net flux represents the integration of genotype, transcription, 
translation and environment which can make even out of “simple” monogenetic disorders 
complex diseases (10).  
 
1.11 Manifestations and presentations 
The enormous number of IEMs causes a wide range of manifestations and therefore nearly 
every presenting case may have a congenital metabolic disease as a possible cause; this is 
especially true in childhood. 
Many deleterious effects of IEMs can be prevented, and long-term damage can be 
minimized, as long as the defects are diagnosed at an early stage. Therefore it is important 
to keep them in mind, especially when treating newborns and infants. 
 
1.12 Symptoms that can be attributed to inborn errors of metabolism 
First signs of an IEM can be poor sucking, feeding refusal, vomiting, excessive weight loss 
and abdominal distension. In such cases it may be adequate to start looking for IEMs. The 
following findings also corroborate the suspicion of an IEM: 
 
- the pregnancy and delivery were both normal (maternal metabolism is not affected) 
- the patient was well for the first few days of life (symptom-free period) 
- the patient becomes ill during a catabolic state due to fasting or infection (intoxication) 
- after each feeding the symptoms worsen (accumulation of substrate that cannot be metabolized) 
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1.13 Diagnosis of inborn errors of metabolism 
IEMs should always be considered in the differential diagnosis when treating a newborn 
presenting with one of the above mentioned symptoms. The following laboratory studies can 
provide clues for the diagnosis: complete blood count, urine analysis, blood gases, serum 
electrolytes, blood glucose and lactate, plasma ammonia, reducing substances in the urine, 
urinary ketones, quantitative plasma and urinary amino acids, urinary organic acids and 
acylcarnitines in dried blood spots (11). Specific tests include enzymatic assays for specific 
enzymes from leukocytes, a skin biopsy (fibroblasts) or a tissue biopsy or necropsy (mainly 
liver or muscle). DNA sequencing is often used for confirmation and genetic counseling. 
 
1.14 Prenatal diagnosis of inborn errors of metabolism 
Many of the diagnostic techniques used for diagnosing IEMs in patients can also be used for 
prenatal diagnosis of IEMs. Metabolites can be measured in amniotic fluid and DNA isolated 
from chorionic villi can be used for sequencing. Also, cultured chorionic villi or amniocytes 
can be used for enzymatic assays. Because the collection of chorionic villi entails a risk of 
miscarriage, novel methods for non-invasive prenatal diagnosis (NIPD) are now being tested. 
They focus on enriching free fetal DNA that circulates in the plasma of the pregnant woman 
(12, 13). NIPD is established for fetal Rhesus determination as well as for fetal sex 
determination in women at risk of a sex-linked genetic disorder (14). 
 
1.15 Therapy of inborn errors of metabolism 
Many patients suffering from an IEM need to follow a strict dietary regimen lacking the 
substance that cannot be catabolized. During episodes of metabolic decompensation high 
dose glucose, insulin and lipids are used to prevent catabolism and promote anabolism. One 
of the few universal therapies available for the management of metabolic defects is dietary 
supplementation with L-carnitine and/or glycine. This enhances the body‟s endogenous 
ability to remove harmful, accumulated metabolites caused by a block in a metabolic 
pathway (15-17). Endogenous detoxification can be divided into two phases. Phase 1 
reactions include oxidation, reduction and hydroxylation reactions that usually detoxify 
xenobiotic substances. Phase 2 includes the conjugation of xenobiotic and endogenous 
toxins (e.g.: to carnitine or glycine) in order to facilitate their urinary excretion as a conjugated 
metabolite (18-22). For some IEMs, especially for lysosomal storage disorders, enzyme 
replacement therapies are available (23). 
For more than 20 years, gene therapy has also been investigated as a treatment option for 
IEMs, especially for phenylketonuria (PKU) (24). Recent results in mice showed that muscle-
directed gene therapy using adeno-associated virus 2 could be a viable alternative treatment 
for PKU (25). Also other promising therapeutic strategies for the treatment of IEMs have 
 6 
emerged recently such as chaperone therapies to enhance the stability of mutated proteins, 
compounds that modulate ribosome specificity thereby enabling the read-through of 
nonsense mutations, or antisense morpholinos inhibiting miss-splicing that is caused by 
intronic mutations leading to the inclusion of a cryptic exon into the mature mRNA (26-28). 
 
1.16 Future aspects of the study of inborn errors of metabolism 
With more and more knowledge on IEM's available, it is increasingly recognized that they are 
not mainly Mendelian traits but represent good examples of complex gene-environment 
interactions and, more specifically, gene-nutrient interactions leading to complex diseases 
(10, 29, 30). Furthermore, metabolism and detoxification of endogenous substances in 
individuals with IEMs may play a major role in determining the phenotype and prognosis. 
IEMs are therefore potentially powerful models to learn to dissect the even more complex 
multifactorial diseases such as common cancers, epilepsy, diabetes, multiple sclerosis etc. 
In complex diseases, it has been proposed that a network of metabolite fluxes might be 
subtly altered to cause a phenotype (30). It is possible that an individual‟s genomic variant 
affects metabolite flux in a subtle fashion, without evidence of clinical disease. The 
cumulative effects of multiple sequence variations on a network of metabolite fluxes might, 
however, be sufficient to surpass the clinical threshold for disease, either alone or in 
combination with environmental factors (30, 31). 
Recent findings in transcriptional research have shown that the transcriptome is considerably 
larger and more divergently expressed than was previously thought. For example small 
physiologically functional RNAs, miRNAs, are now known to be nested within intronic regions 
of primary RNA transcripts (32, 33). It is commonly accepted that they play important roles in 
post-transcriptional gene-regulation and are sensitive to environmental and dietary stimuli 
(34, 35). Their role in IEMs however remains to be determined. 
 
1.17 Newborn screening 
The origins of newborn screening (NBS) for IEMs can be tracked back some 75 years. In 
1934, Asbjorn Fölling, a Norwegian biochemist, was asked to examine two severely mentally 
handicapped children of a former student. He found that they excreted high amounts of 
phenylketones in their urine (36). This was due to the inability to convert phenylalanine to 
tyrosine, a condition nowadays known as PKU. 25 years after this discovery, a 
phenylalanine-restricted diet became commercially available. Once this diet was available, 
asymptomatic infants with PKU that were identified and diagnosed during the first few weeks 
of life could be administered this diet in order to prevent permanent brain damage. Later it 
was shown that high levels of phenylalanine lead to disturbances in brain energy 
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metabolism, the creation of high energy phosphates and subsequently to neurotoxicity (37, 
38). 
In 1963, Robert Guthrie developed an assay that allowed screening of newborns for PKU: a 
few drops of blood collected on a filter paper within the first 2-3 days of life were used for 
rapid analysis of elevated phenylalanine (39). 
The advent of novel experimental techniques, such as a range of mass-spectrometry 
methods, are heralding a paradigm-shift that will have a great impact on the quality of life of 
people with metabolic disorders (11). The US, Australia and many European countries have 
implemented extended population newborn screening programs using tandem mass 
spectrometry (MS/MS). With this approach it is possible to detect approximately 30 IEMs 
simultaneously at a presymptomatic clinical stage using the same filter paper card blood 
spots (40, 41). NBS programs revealed that the incidence of metabolic diseases is much 
higher than traditionally thought; in Australia for example the prevalence of IEMs was found 
to be around 1:6'500 (PKU excluded)(42). 
As far more cases are diagnosed by NBS than previously by clinical symptoms, it remains to 
e clarified what proportion of detected individuals will become clinically symptomatic (42). 
More than 40 years ago the World Health Organization has defined criteria for including a 
disorder into a (newborn) screening program (43). Accordingly, a disorder screened for 
should meet the following criteria: 
 
- it causes significant morbidity and/or mortality 
- an effective treatment is available 
- there is some time before the onset of symptoms so that intervention can be effective 
- the screening method and the assay is clinically validated 
- the screening is economically “reasonable” 
- the natural history of the disease is understood 
- the incidence in the population to be screened is known and significant 
 
Many of the disorders that are screened for today do not fulfill all these criteria. One example 
is 3-MCC that is discussed in section 2.2.3.4. 
 
2 Organic Acidemias 
Organic acidemias (organic acidurias) are characterized by the urinary excretion of organic 
acids. They are primarily the result of enzyme deficiencies in the catabolic pathways of 
amino acids, carbohydrates or the beta oxidation of fatty acids (44). The relevant pathways 
are depicted in Figures 2 and 4. 
Affected babies are often full-term born babies that are initially symptom-free and then 
suddenly undergo relentless deterioration without apparent cause and are not responsive to 
symptomatic therapy. The reason for this rapid deterioration is the catabolic state of the 
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newborn in the first few days of life leading to accumulation of acyl-CoA derivatives that 
cannot be further metabolized followed by progressive intoxication. First signs include poor 
feeding and drowsiness that can develop into an unexplained progressive coma. Changes in 
the central nervous system (CNS) can include cerebral oedema and arousing suspicion of 
CNS infection. Further neuro-vegetative signs that may appear later include respiratory 
distress, hiccups, apnoeas and hypothermia. Additional phenotypes can include axial 
hypotonia, limb hypotonia, tremors, myoclonic jerks and hepatomegaly. 
Typically, affected children have severe acidosis, ketosis and hyperammonemia. These 
findings can be accompanied by hypoglycemia and electrolyte abnormalities. Blood analysis 
can detect neutropenia, thrombocytopenia or pancytopenia due to bone marrow suppression. 
As early diagnosis and emergency treatment can prevent CNS dysfunction, it is required that 
toxins are removed immediately after diagnosis. 
Initial treatment includes intravenous re-hydration and correction of acidosis, 
hyperammonemia, hypoglycemia and electrolyte abnormalities. To prevent further 
catabolism and promote anabolism patients are treated with high glucose, lipids and insulin. 
In addition, L-carnitine is administered to promote detoxification and to prevent secondary 
carnitine deficiency. Hemodialysis or hemofiltration may also be necessary in cases with 
severe acidosis or hyperammonemia (45). In methylmalonic aciduria (MMA) and propionic 
acidemia (PA) the administration of carglumic acid may be considered. The accumulation of 
propionyl-CoA in these disorders can lead to reduced synthesis of N-acetyl-glutamate, the 
physiological activator of the enzyme carbamyl phosphate synthetase 1 (CPS1). CPS1 plays 
an important role in the detoxification of nitrogen and can be activated by carglumic acid (46). 
In survivors of the difficult initial decompensation a strict diet low in natural protein and 
supplemented with precursor-free amino acid mixtures and vitamins is essential to limit the 
formation of organic acid byproducts and enable normal growth. Phases of acute metabolic 
decompensation due to catabolic stress following intercurrent illness usually require 
intravenous therapy due to vomiting and nausea. During the acute phase protein is 
withdrawn from the diet for 24 to 48 hours, later a low-protein diet is gradually reintroduced 
(47, 48). 
Prevention and early treatment of such recurrent episodes of metabolic imbalance is crucial. 
Metabolic derangement is potentially life-threatening and can be the cause of neurological 
sequels at any age. 
 
2.1 Metabolism of branched-chain amino acids 
Disorders in the degradation pathway of the three branched-chain amino acids (BCAA) 
leucine, isoleucine and valine are collectively termed branched-chain organic acidurias. The 
five most common ones include maple syrup urine disease (MSUD), isovaleric acidemia 
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(IVA), 3-methylcrotonylglycinuria (MCC), methylmalonic aciduria (MMA), and propionic 
aciduria (PA) (49). 
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Figure 2: Degradation pathway of branched-chain amino acids and the corresponding enzymes. 
(1) Branched-chain oxo-(or keto-) acid dehydrogenase; (2) isovaleryl-coenzyme A (CoA) dehydrogenase; (3) 3-
methylcrotonyl-CoA carboxylase; (4) 3-methylglutaconyl-CoA hydratase; (5) 3-hydroxy-3-methylglutaryl-CoA 
lyase; (6) 2-methylacetoacetyl-CoA thiolase; (7) 3-hydroxyisobutyryl-CoA deacylase; (8) 3-hydroxyisobutyric 
dehydrogenase; (9) methylmalonylsemialdehyde dehydrogenase; (10) acetyl-CoA carboxylase (in mitochondria); 
(11) propionyl-CoA carboxylase; (12) methylmalonyl-CoA mutase; (13) malonyl-CoA decarboxylase. Enzyme 
defects are indicated by solid bars. Figure modified from (49). 
 
2.1.1 Maple syrup urine disease (MSUD) 
Deficiency of branched-chain oxo- (or keto-) acid dehydrogenase, the second step in the 
catabolism of the three BCAA is the cause of MSUD. The active enzyme (Figure 2, enzyme 
1) is composed of three subunits (E1α, E1β and E2), a decarboxylase that requires thiamine 
(vitamin B1) as a coenzyme, a dihydrolipoyl acyltransferase and a dihydrolipoamine 
dehydrogenase. A deficiency of any of these three subunits can cause MSUD. 
MSUD is inherited as an autosomal recessive trait. The incidence is around 1:300'000. Up to 
date over 50 mutations have been found in the three responsible genes. They give rise to 
either the severe classical (75 % of all affected patients) or the intermediate phenotypes. In 
experimental systems gene therapy has already been tested (50). 
Prenatal diagnosis relies on enzymatic assays or mutation analysis in cultured amniocytes or 
in chorionic villi. 
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Enzyme deficiency results in elevated branched-chain 2-oxo (keto-) acids in plasma, urine 
and cerebrospinal fluid. Due to the reversibility of the first reaction in the metabolism of 
BCAAs, the BCAAs also accumulate. 
Together with the occurrence of the first symptoms, the patient excretes urine with an 
intensive maple syrup-like odor. The main laboratory finding is the presence of elevated 
BCAAs as well as allo-isoleucine in plasma and 2-oxo acids in the urine. Patients usually do 
not display severe dehydration, metabolic acidosis, accumulation of lactate or a change in 
blood cell count. Ammonia levels are usually normal but may be mildly elevated 
(<200 µmol/l). 
Acutely ill newborns need emergency treatment in order to protect the brain from permanent 
damage. When high-energy enteral or parenteral nutrition alone is insufficient to lower 
plasma leucine levels, hemodialysis or hemofiltration are applied in order to lower plasma 
leucine levels to 1 mmol/l or less. BCAA intake has to be adjusted according to plasma levels 
measured daily during the time of recovery. Administration of thiamine (5 mg/kg/d) for at 
least three weeks has been shown to be able to improve BCAA tolerance in a few patients. 
Normal leucine tolerance has however never been restored (51). 
The goal of the life-long therapy is to keep plasma BCAA levels near to normal concentration 
when measured 2-3 h after a meal. The diet is based on keeping leucine levels as normal as 
possible as leucine is the most toxic amino acid. Therefore, occasionally free isoleucine and 
valine must be added to the diet in order to provide the body requirement of those two amino 
acids. 
Nowadays patients with MSUD are expected to survive the difficult newborn period. 
Generally they are healthy between times of metabolic imbalance. Some even develop 
normally and attend regular schools. However, during acute metabolic crisis due to 
intercurrent illness, patients may present with pancreatitis, epidermal lesions due to protein 
malnutrition or cerebral oedema that may cause unexpected death. The average intellectual 
performance is far below normal. Intellectual performance is inversely related to the time 
during which plasma leucine levels remained above 1 mmol/l and is also dependent on the 
long-term metabolic control. 
 
2.1.2 Isovaleric acidemia (IVA) 
Deficiency of isovaleryl-CoA dehydrogenase (Figure 2, enzyme 2), a mitochondrial 
flavoprotein that transfers electrons to the respiratory chain via the electron transfer 
flavoprotein (ETF) leads to isovaleric acidemia. Deficiency of ETF itself results in multiple 
acyl-CoA-dehydrogenase deficiencies (glutaric aciduria type II, (52)). 
IVA is inherited as an autosomal recessive trait. The incidence is around 1:200‟000. Various 
mutations have been described in the IVD gene. One mutation (p. A282V) is particularly 
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common in patients detected by newborn screening. They show mildly elevated metabolites 
and all of them have remained asymptomatic to date (53). 
The defect causing IVA leads to accumulation of free isovaleric acid that is converted to 3-
hydroxyisovaleric acid and N-isovalerylglycine. It can also form complexes with carnitine 
producing isovaleryl-carnitine. N-isovalerylglycine and 3-hydroxyisovaleric acid are rapidly 
excreted and are easily measured in the urine; isovaleryl-carnitine is found predominantly in 
the plasma. 
Oral administration of L-glycine and intravenous L-carnitine are effective means of 
detoxification and treatment. The need for the combined supplementation is still controversial 
but can be useful during metabolic crisis when there is an increased need for detoxifying 
agents (15). 
Blood exchange transfusions may be necessary for toxin removal in newborns who present 
in a poor clinical condition that does not allow the effective use of these alternate 
detoxification pathways. 
Long-term therapy consists of a low protein diet supplemented with a leucine free amino acid 
mixture, vitamins, oral carnitine and glycine. The intake of leucine and thus natural protein 
can be gradually increased during the first year of life. The overall prognosis is better than for 
patients suffering from propionic acidemia, methylmalonic aciduria or MSUD. Intellectual 
outcome is dependent on early diagnosis, correct treatment and long-term compliance later 
in life. 
 
2.1.3 3-Methylcrotonylglycinuria (MCC) 
3-Methylcrotonylglycinuria is caused by defects in 3-methylcrotonyl-CoA carboxylase, a 
biotin dependent enzyme consisting of two subunits (α and β) encoded by the genes MCCA 
and MCCB respectively. MCC is discussed in detail in the section dealing with the biotin-
dependent carboxylases (2.2.3.4). 
 
2.1.4 Propionic acidemia (PA) 
Propionic acidemia is inherited as an autosomal recessive trait and is caused by a deficiency 
of propionyl-CoA carboxylase, (PCC; Figure 2: enzyme 11; Figure 4: enzyme 1) one of the 
five biotin-dependent carboxylases found in humans. PCC is an enzyme located in the 
mitochondrial matrix that is composed of two non-identical subunits (α and β) encoded by the 
genes PCCA and PCCB respectively (54). Mutations in both genes have been found to lead 
to PA. PCC is involved in the catabolism of various essential amino acids like methionine, 
isoleucine, threonine and valine, as well as odd-chain fatty acids and cholesterol. 
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A deficiency results in markedly increased concentrations of free propionate in blood and 
urine. Major diagnostic metabolites include propionyl-carnitine in plasma, and 3-
hydroxypropionate and methylcitrate in urine. 
In patients with abnormal biotin metabolism, propionyl-CoA accumulation is also found due to 
multiple carboxylase deficiency, resulting in defective activity of all biotin-dependent 
carboxylases (see section 2.2.3 and Figure 7).  
PA is a severe organic acidemia. This is due to the fact that the excretion of propionic acid 
via the urine is negligible and no alternative pathway is sufficient to detoxify the body. 
Patients are at high risk for life-threatening episodes of metabolic acidemia and with 
consecutive developmental delay, neurological symptoms and cardiomyopathy (55). During 
acute metabolic decompensation newborns and patients suffering from PA may thus need 
exogenous toxin removal procedures. 
Living-donor liver transplantation has been shown to be beneficial in severely affected 
patients (56) but does not always prevent complications such a metabolic stroke. As a long-
term treatment, gene-therapy using adeno-associated vectors is currently being investigated 
in mice (57). Prenatal diagnosis can be performed by mutation analysis using chorionic villi 
(58). For more clinical signs, diagnostic testing, therapy and prognosis see methylmalonic 
aciduria.  
 
2.1.5 Methylmalonic aciduria (MMA) 
Methylmalonic aciduria (MMA) is caused by a deficiency of methylmalonyl-CoA mutase 
(MUT; Figure 2, enzyme 12; Figure 4, enzyme 3). Methylmalonyl-CoA mutase is localized 
within mitochondria and catalyzes the conversion of methylmalonyl-CoA to succinyl-CoA 
(Figure 3). 
 
Figure 3: Methylmalonyl-CoA mutase reaction 
mechanism. Homolytic rupture of the metalloalkyl 
cobalt – carbon bond generates cob(II)alamin and the 
deoxyadenosyl radical (step i). The latter initiates the 
isomerization reaction by the abstraction of a hydrogen 
atom from the substrate to yield a substrate-centered 
radical (step ii). The substrate radical then rearranges 
yielding a product-centered radical (step iii). The 
product-centered radical then re-abstracts a hydrogen 
atom from deoxyadenosine in the second hydrogen 
transfer step (step iv). Recombination of the cofactor-
based radicals completes the turnover cycle (step v). 
MCoA and SCoA refer to methylmalonyl-CoA and 
succinyl-CoA, respectively. 
Figure with permission from (59).  
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About half of the MMA patients have a mutase apoenzyme defect that is further divided into 
mut0 and mut- groups. Whereas patients with the mut0 defect have a complete loss of 
enzyme activity, patients with the mut- defect still have some residual activity and may be 
responsive to cobalamin (vitamin B12) (60). 
Various defects in intracellular cobalamin metabolism can also lead to MMA (Figure 16): 
while the cblF and cblC defect lead to a combination of methylmalonic aciduria and 
homocystinuria, the cblA and cblB defects lead to isolated methylmalonic aciduria. The cblD 
defect is special in that it can cause three phenotypes, isolated methylmalonic aciduria, 
isolated homocystinuria or a combination of both (see section 2.2.4.2). 
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Figure 4: Metabolic pathways involved in methylmalonic aciduria. Propionyl-CoA (P-CoA), an intermediate 
metabolite in the common catabolic pathways of branched-chain amino acids, cholesterol, odd-numbered fatty 
acids, thymine and uracil, is carboxylated by propionyl-CoA carboxylase (1; reversibility of reaction is minor) to D-
methylmalonyl-CoA. D-Methylmalonyl-CoA is converted to L-methylmalonyl-CoA by methylmalonyl-CoA 
epimerase (2, reversible reaction). Methylmalonyl-CoA mutase (MUT; 3) catalyses the conversion of L-
methylmalonyl-CoA to succinyl-CoA, an intermediate of the TCA cycle. This reaction is partly reversible and is 
modulated by propionyl-CoA flux. Deficiency of MUT leads to alternative propionate oxidation. Propionate is 
derived from hydrolysis of P-CoA. β- and/or ω-oxidation of P-CoA and propionate results in formation of 3-
hydroxypropionate. Gut bacteria also form propionate and 3-hydroxypropionate, which may aggravate metabolic 
crisis. Succinyl-CoA is converted to succinate by succinate-CoA ligase (4). 
Incorporation of P-CoA instead of acetyl-CoA into the TCA cycle leads to the formation of 2-methylcitrate, 
catalyzed by citrate synthase (5). Other metabolites also accumulate in methylmalonic acidurias: methylmalonate 
is derived from hydrolysis of methylmalonyl-CoA; conjugation of P-CoA with glycine, alanine or L-carnitine 
produces propionylglycine, propionylalanine and propionylcarnitine. Figure modified from (61). 
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Mild elevations of MMA can also be found in defects of methylmalonyl-CoA epimerase 
(MCEE; Figure 4, enzyme 2), an enzyme converting D-methylmalonyl-CoA to L-
methylmalonyl-CoA (62) or in defects of one of the various subunits of succinate-CoA ligase 
(SUCL; Figure 4, enzyme 4), an enzyme complex catalyzing the conversion of succinyl-CoA 
to succinate in the TCA cycle. Apart from these defects there are also cases of unresolved 
mild and benign MMA elevations (63). The total incidence of MMA is about 1:50‟000. 
The various defects leading to MMA are characterized by various amounts of excreted 
methylmalonic acid (Figure 5). As high levels of methylmalonic acid inhibit propionyl-CoA 
carboxylase (PCC; Figure 4, enzyme 1), a secondary accumulation of propionic acid as well 
as other propionyl-CoA metabolites as in PA is usually found in the urine of MMA patients. 
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Figure 5: Urinary MMA levels in various types of disorders. The levels shown are approximations based on 
ranges of values reported in the literature. Mut
0
 and mut
-
 denote a complete loss or residual activity of methylmalonyl-
CoA mutase (MUT). CblA, cblB, cblC, cblD and cblF denote complementation groups of intracellular vitamin B12 
metabolism leading to MMA. MCEE, methylmalonyl-CoA epimerase deficiency; MMA, methylmalonic aciduria; 
SUCLG1, succinate-CoA ligase, alpha subunit; SUCLA2, succinate-CoA ligase, ADP-forming beta subunit. 
Figure from (64). 
 
2.1.5.1 Clinical findings in methylmalonic aciduria 
Accumulation of methylmalonic as well as propionic acid cause the so called "intoxication type" 
neurological distress with acute and rapidly progressive neurological signs (65). Infants present 
during the first days of life with signs of acute metabolic decompensation including vomiting, 
respiratory distress, feeding intolerance, hepatomegaly, hypotonia, encephalopathy, lethargy 
and severe acidosis. If not treated aggressively, these symptoms may progress rapidly and lead 
to coma and death (61, 66, 67). Acute heart failure due to cardiomyopathy, pancreatitis and 
epidermal lesions may also be present. In contrast to MSUD, IVA, PA and MMA patients 
frequently present with dehydration and moderate hepatomegaly. Also metabolic acidosis 
(pH<7.30) with an increased anion gap and ketonuria can be observed. Hyperammonemia is a 
common finding and may be very high (>800 µmol/l). In these cases it can lead to respiratory 
alkalosis and the disease can be misdiagnosed as a urea cycle disorder. 
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Neurological problems as well as renal and cardiac symptoms may present during intercurrent 
episodes or may progressively arise as late complications. Neuro-imaging in some MMA 
patients revealed symmetric degeneration of the basal ganglia; furthermore, histopathology 
showed severe necrosis in the globus pallidus and mild spongiosis of the subthalamic nucleus 
(68, 69). These pathologic findings have been suggested to be caused by "metabolic stroke" 
due to the accumulation of toxic organic acids (70). A recent analysis of 52 children with MMA 
showed that the radiological findings are unspecific, however combined incidence of common 
clinical and radiological findings should raise the suspicion of MMA (71). 
Patients with defects in cblB or mut0 usually present with a severe phenotype with vomiting, 
failure to thrive, hypotonia and encephalopathy (72) while cblA and mut- patients usually have a 
milder clinical spectrum and a higher survival rate (73).  
 
MMA in combination with homocystinuria in patients with a defect in cobalamin (vitamin B12) 
metabolism, namely in the cblF, cblC or cblD complementation groups (see section 2.2.4.2) 
usually present with a different clinical picture than patients with isolated MMA (cblA and cblB). 
Based on the age of onset of symptoms, 2 distinct clinical forms of the cblC defects have been 
recognized: The early-onset form, in which symptoms appear in the first year of life, include a 
multisystemic disease with severe neurological signs associated with characteristic 
hematological, renal and gastrointestinal manifestations. The long-term prognosis in these 
cases is usually poor. Patients with a later-onset form present with a milder clinical phenotype 
with moderate neurological involvement and behavioral disturbances (74). 
Patients with the cblD defect can present with various biochemical and clinical phenotypes, 
namely with isolated MMA, isolated homocystinuria or the combination of these two, depending 
on the nature and position of the mutation within the MMADHC gene see chapter 2 (75, 76). 
Mutations in SUCL subunits lead to mitochondrial DNA depletion; clinical symptoms include 
encephalomyopathy, dystonia, deafness and fatal lactic acidosis (77, 78). 
 
2.1.5.2 Diagnosis of methylmalonic aciduria 
IVA, PA and MMA are diagnosed by their specific organic acid profiles. Prenatal diagnosis can 
be performed by direct measurement of metabolites in amniotic fluid using various methods or 
by molecular genetic analysis if the mutations of the index patient are known (79, 80). 
Diagnosis of MMA is based on the presence of characteristic compounds in body fluids. 
Methylmalonic acid, 2-methylcitric acid and 3-hydroxypropionic acid are elevated in MMA 
patients and can be detected by GC/MS. 2-Methylcitrate, a metabolite frequently detected in 
MMA and PA patients is formed by condensation of propionyl-CoA and oxaloacetate, a reaction 
catalyzed by citrate synthase (Figure 4, enzyme 5).  
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Plasma acylcarnitine analysis by MS/MS shows an abnormal profile with propionylcarnitine 
being the predominant carnitine ester. Furthermore the ratio of propionylcarnitine to free 
carnitine is greatly increased. 
Due to the accumulation of propionyl-CoA in MMA and PA, ureagenesis is disturbed. This is due 
to propionyl-CoA-induced inhibition of N-acetylglutamate synthetase, resulting in decreased N-
acetylglutamate, an allosteric activator required for carbamoylphosphate synthase I (81), and 
subsequently hyperammonemia. 
 
2.1.5.3 Pathogenesis of methylmalonic aciduria 
Methylcitrate exerts several inhibitory effects on enzymes of the TCA cycle and on the 
mitochondrial citrate transporter which facilitates mitochondrial accumulation of methylcitrate. 
Impaired energy metabolism (due to dysregulation of the TCA cycle) within neurons can lead to 
reduced ability to maintain the normal resting membrane potential due to a depletion of ATP. 
This can lead to an uncontrolled influx of Na+ leading to increase in activity of a glutamate 
receptor that regulates whole cell current and plays important roles in regulating plasticity and 
toxicity in neurons (82). Malonate, another metabolite, is only slightly elevated, it might only play 
a minor role in MMA-induced neurotoxicity. 
It is hypothesized that accumulation of these organic acids leads to mitochondrial dysfunction. 
The fact that patients with inherited deficiency of mitochondrial complex II also show 
symmetrical lesions in the basal ganglia corroborates this hypothesis (83). Furthermore, MMA 
induces neuronal damage in cultured embryonic rat striatal cells at concentrations encountered 
in affected patients (84, 85). 
Elevated ammonium levels might also be a causative agent in MMA-induced neurotoxicity (65). 
The pathogenesis of acute heart failure in MMA and PA patients is still unclear (86), the same is 
true for renal failure; however for the latter, tubulointerstitial nephritis as well as accumulating 
methylmalonic acid in renal tubular cells, leading to disturbance of cellular energy metabolism, 
might play important roles (87). 
 
2.1.5.4 Treatment of methylmalonic aciduria 
As some forms of MMA with neonatal-onset are responsive to vitamin B12, parenteral vitamin 
therapy, starting with 1-2 mg hydroxocobalamin per day for a few days, must be tested. B12 
responsiveness leads to a prompt decrease in MMA and propionyl-CoA by-products. Those 
MMA patients responsive to B12 are usually characterized by a mild disease and a good 
outcome and require only mild protein restriction. 
Otherwise the management of MMA and PA remains difficult. Treatment can be divided into 
emergency treatment and long-term treatment (88). 
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Emergency treatment is based on avoidance of nitrogen intake and the inhibition of endogenous 
catabolism by provision of adequate caloric intake as parenteral glucose. Insulin may be 
administered utilizing its anabolism-promoting effect. Metabolic acidosis is usually corrected by 
rehydration but may require bicarbonate therapy if pH does not normalize. Intravenous 
administration of carnitine is used to buffer the intramitochondrial accumulation of propionyl-
CoA. 
Patients unresponsive to medical therapy within the first few hours need extracorporeal removal 
of toxic metabolites using hemofiltration or hemodialysis (89). 
Long-term treatment is based on a low-protein high-energy diet low in propiogenic substances 
supplemented with vitamins and trace elements. 
Valine is one of the direct precursors of propionyl-CoA, therefore natural protein intake is 
adjusted to valine intake as the basis. Additionally, an intake of an amino acid mixture free of 
valine, isoleucine, methionine and threonine may be required in order to enable normal growth 
and prevent protein deficiency. Long-term oral administration of L-carnitine (100 mg/kg/day) 
seems to be effective in preventing carnitine depletion as well as enhancing urinary excretion of 
carnitine esters and therefore reducing propionate toxicity (90). 
Another considerable source of propionate are bacteria in the intestine. Metronidazole inhibits 
anaerobic colonic flora and can reduce urinary excretion of propionate metabolites by up to 
40 %. The recommended therapy regimen is to take metronidazole for 10 consecutive days at a 
dose of 10-20 mg/kg once every month (90). 
Recent attempts of using liver transplantation have showed that replacement of the liver only 
partly corrects the enzymatic defect. Urinary metabolites are still excreted and renal failure and 
neurological deterioration are not cured by liver transplantation (91-93). Kidney transplantation 
may be necessary in the second decade of life as chronic renal failure is increasingly 
recognized in MMA patients, especially in those with mut0 and cblB defects (94). For patients in 
end-stage renal failure, combined liver-kidney transplantation could represent a better strategy 
than liver transplantation alone (95). 
A few reports can be found on successful pregnancies in women with MMA. Protein restriction 
in combination with vitamin B12, carnitine and bicarbonate supplementation resulted in good 
outcome with birth of healthy children. Glucose infusions were used to prevent catabolism in the 
post-partum period (96-98). 
 
2.2 Vitamins with a focus on biotin and cobalamin 
 
2.2.1 Introduction 
Vitamins are organic compounds that are required by an organism in small amounts and must 
be obtained from the diet. They are classified by their biological and chemical activity, not their 
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structure. Vitamins serve diverse biochemical functions, including function as hormones (e.g. 
vitamin D), antioxidants (e.g. vitamin E), and mediators of cell signalling and regulators of cell 
and tissue growth and differentiation (e.g. vitamin A). The B complex vitamins represents the 
largest group of vitamins functioning as coenzymes, that act as catalysts and substrates in 
metabolism. A list of vitamins is given in Table 1. 
Name Compound Source Discovered Solubility  RDI* Deficiency disease
Vitamin A Retinoids Cod liver oil 1909 Fat 900 µgNight-blindness and Keratomalacia
Vitamin B1 Thiamine Rice bran 1912 Water 1.2 mgBeriberi, Wernicke-Korsakoff syndrome
Vitamin B2 Riboflavin Eggs 1920 Water 1.3 mgAriboflavinosis
Vitamin B3 Niacin, niacinamide Liver 1936 Water 16 mgPellagra
Vitamin B5 Pantothenic acid Liver 1931 Water 5 mgParesthesia
Vitamin B6 Pyridoxine, 
pyridoxamine, pyridoxal
Rice bran 1934 Water 1.5 mgAnemia
Vitamin B7 Biotin Liver 1931 Water 30 µgDermatitis, enteritis
Vitamin B9 Folic acid, folinic acid Liver 1941 Water 400 µgDeficiency during pregnancy is 
associated with birth defects, such as 
neural tube defects
Vitamin B12 various Cobalamins Liver 1926 Water 2.4 µgMegaloblastic anemia
Vitamin C Ascorbic acid Lemons 1912 Water 90.0 mgScurvy
Vitamin D Ergocalciferol, 
cholecalciferol
Cod liver oil 1918 Fat 10 µgRickets and Osteomalacia
Vitamin E Tocopherols, tocotrienols Wheat germ 
oil and liver
1922 Fat 15 mgDeficiency is very rare; mild hemolytic 
anemia in newborn infants
Vitamin K phylloquinone, 
menaquinones
Alfalfa 1929 Fat 120 µgBleeding diathesis
*: recommended dietary intake
 
Table 1: list of vitamins and their properties. 
 
Deficiencies of vitamins are classified as either primary or secondary. A primary deficiency 
refers to a state in which an organism does not acquire enough of the vitamin with the diet. A 
secondary deficiency may be due to an underlying disorder that prevents or limits the 
absorption or use of the vitamin. This is most likely due to a “lifestyle factor” such as 
smoking, exposure to sunlight, excessive alcohol consumption and many more, or more 
interesting to researchers - due to a genetic defect that interferes with the absorption or use 
of the vitamin. 
People consuming a varied diet are unlikely to develop a severe primary vitamin deficiency. 
In contrast, restrictive diets caused by vegetarianism, food allergies, poor availability of 
certain food stuffs, malnutrition in general and many more, have the potential to cause 
prolonged vitamin deficits, which may result in potentially fatal diseases (99-102). 
 
2.2.2 Biotin (vitamin B7) 
Biotin was discovered around 1900 when it was shown to be essential for the growth of 
certain yeast strains. It was not until 1943 when the chemical formula (Figure 6) was 
elucidated (103). In humans biotin is necessary for cell growth, the formation of fatty acids 
and the metabolism of fats and amino acids. Biotin-containing foods include berries, cereals, 
liver, milk, nuts, vegetables and yeast. 
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Figure 6: Structure of biotin In this sketch D-biotin is 
bound to a protein via a lysyl residue. 
 
 
 
 
Biotin is taken up in the diet in the free as well as the protein-bound form. The enzyme 
biotinidase releases the protein-bound biotin and makes it available for intestinal uptake. 
Biotin is taken up in the small and to some extent also in the large intestine by carrier-
mediated processes (104). After successful uptake it enters the bloodstream and is taken up 
by target cells again by carrier-mediated processes (105). 
 
2.2.2.1 Biotin deficiency 
Biotin deficiency can lead to seizures, hypotonia, ataxia, dermatitis, hair loss, mental 
retardation, ketoacidosis and organic aciduria (106). In the US, it was shown that about half 
of the pregnant women are marginally biotin deficient (107). While in humans this does not 
seem to have a great impact, in animal models this situation has been shown to be 
teratogenic (108). Recently, connections between biotin and gene expression patterns 
caught attention as various histones, protein components of chromatin, are biotinylated 
(109). In animal models it was shown that a decrease in histone biotinylation caused 
abnormal gene expression and reduced life-span as well as heat resistance (110). The 
mechanisms whereby histone biotinylation leads to gene repression still need to be 
elucidated and the extent to which biotinylation of histones alters gene expression in humans 
warrants further investigation (107). 
 
2.2.3 Biotin-dependent carboxylases and intracellular biotin metabolism 
In humans, five biotin-dependent carboxylases have been described so far (Table 2): acetyl-
CoA carboxylase 1 and 2 (ACC1 and ACC2), 3-methylcrotonyl-CoA carboxylase (MCC), 
propionyl-CoA carboxylase (PCC) and pyruvate carboxylase (PC) (106, 111). 
ACC2
3q21-q2213q3211q13.35q12-133q25-2712q24.117q21locus
15242117194854exons
58.277.4129.661.380.5279.7269size (kDa)
539703117856372524832383amino acids
(αβ)6α4(αβ)6polymeric?polymeric?structure
βααβα21subunits
mitochondriamitochondriamitochondriamitochondriacytosoliclocation
PCCPCMCCACC1
 
Table 2: Table of the five biotin-dependent carboxylases found in humans indicating their localization, 
hypothetical structure, size and genetic organization 
Lysyl residue
D-Biotin
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Owing to the role of the carboxylases in various metabolic pathways like gluconeogenesis, 
fatty acid synthesis and the catabolism of several amino acids (Figure 7), their deficiency 
may lead to profound metabolic derangement, eliciting neurological symptoms and a 
characteristic organic aciduria (106). 
 
PC
Glucose
Malonyl-CoA
Fatty acids
ACC
MCC
Leucine
3-Methylcrotonyl-CoA
Acetyl-CoA
3-Methylglutaconyl-CoA
Lac
PYR
Citrate
OAA
Succinyl-CoA
Citric acid
cycle
Propionyl-CoA
Methylmalonyl-CoA
Valine
Isoleucine
Methionine
Threonine
Odd-chain fatty acids
Cholesterol side-chain
PCC
β-oxidation
 
Figure 7: The carboxylase deficiencies. Sites of enzyme defects are indicated by black bars. Full lines indicate 
one enzyme and dashed lines indicate that several enzymes are involved. Pyr, pyruvate; lac, lactate; OAA, 
oxaloacetate; MCC, 3-methylcrotonyl-CoA carboxylase; PCC, propionyl-CoA carboxylase; PC, pyruvate 
carboxylase; ACC, acetyl-CoA carboxylase. Figure modified with permission from (112). 
 
The five biotin-dependent carboxylases all have three structurally conserved functional 
domains: the biotin carboxyl carrier domain, which carries the biotin prosthetic group; the 
biotin carboxylation domain, which catalyzes the carboxylation of biotin and the 
carboxyltransferase domain, which catalyzes the transfer of a carboxyl group from 
carboxybiotin to the organic substrate specific for each carboxylase (113). The genes for all 
human carboxylases have been cloned and characterized (54, 114-116). 
The intracellular formation of the active carboxylase (holocarboxylase) occurs in two partial 
reactions: After the formation of the biotinyl-5‟-AMP intermediate, the biotinyl moiety is 
transferred to the apoenzyme, forming the active holoenzyme: 
 
A)
B)
d-biotin + ATP          d-biotinyl-5„AMP + PPi
d-biotinyl-5„AMP + apocarboxylase holocarboxylase + AMP
d-biotin + ATP + apocarboxylase holocarboxylase + AMP + PPiNet:
Mg
2+
Mg
2+
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The action of biotin-dependent enzymes can be expressed as two partial reactions: The first 
reaction involves the formation of the carboxybiotinyl enzyme using bicarbonate as the 
carboxyl donor. In the second reaction, the carboxyl group is then transferred from the 
enzyme-CO2 complex to an acceptor substrate. This mechanism has been shown for all five 
biotin-dependent carboxylases (117). 
 
C)
D)
Net:
Enzyme-biotin + ATP + HCO3
-
Enzyme-biotin-CO2 + ADP + PPi
Enzyme-biotin-CO2 + acceptor Enzyme-biotin + acceptor-CO2
HCO3
-
+ ATP + acceptor acceptor-CO2 + ADP + PPi
Mg
2+
Mg
2+
 
 
The active holocarboxylases are degraded by proteases during the course of normal cellular 
turnover. End-products of this degradation are free amino acids and the small peptide 
biocytin (biotinyl-lysine). The final release of biotin from biocytin is again carried out by 
biotinidase (Figure 8). Deficiency of either biotinidase or holocarboxylase synthetase results 
in multiple carboxylase deficiency (118-121). 
 
biotin
DIET
biocytin
active holocarboxylases
biotin
cycle
free biotinprotein-bound biotin
Biotinidase
incactive carboxylases
proteolytic degradation
lysine Biotinidase
PROTEINS CARBOHYDRATESFATS
Holocarboxylase synthetase
amino acids
 
Figure 8: The intracellular biotin cycle. Biotin is taken up by the diet either in the free or protein-bound form. 
Biotinidase releases free biotin from protein-bound biotin. Holocarboxylase synthetase attaches free biotin to 
inactive carboxylases producing active holocarboxylases. These are important in the synthesis and degradation of 
proteins, amino acids, fats and carbohydrates. Proteolytic degradation of active holocarboxylases leads to the 
release of amino acids and biocytin (biotinyl-lysine). Biotinidase cleaves biocytin thereby releasing free biotin. 
 
2.2.3.1 Acetyl-CoA carboxylase (ACC1 and ACC2, EC 6.4.1.2) 
In humans there are two ACC genes, ACC1 and ACC2 (115). While ACC1 is mainly 
expressed in lipogenic tissues, ACC2 is predominantly found to be expressed in muscle and 
heart (122-124). While ACC1 appears to be localized in the cytosol where it is a major 
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provider of malonyl-CoA that is needed for the synthesis of very long-chain fatty acids, ACC2 
seems to be localized at the mitochondrial membrane and is thought to be responsible for 
mitochondrial fatty acid oxidation (125, 126). As ACC plays pivotal roles in intracellular 
energy metabolism and has been linked to various diseases like cancer, diabetes and 
microbial infections (127, 128), it has become an attractive drug target (129). 
In mice it has been shown that animals lacking ACC1 are embryonically lethal (126). In 
humans, deficiency of ACC has only been reported in one patient, a newborn girl that 
presented with severe respiratory and perinatal problems as well as hypotonic myopathy. 
Later it became clear that she had severe brain damage, persistent myopathy and poor 
growth (130). 
 
2.2.3.2 Pyruvate carboxylase (PC, EC 6.4.1.1) 
PC is a key enzyme in gluconeogenesis and is located in the mitochondrial matrix. It is 
mainly expressed in gluconeogenic tissue where it catalyzes the first step in the synthesis of 
glucose from pyruvate. It is also expressed in lipogenic tissue where it participates in the 
formation of acetyl groups and reducing groups for transport from mitochondria to the cytosol 
(114). It has been suggested that PC is also involved in regulating glucose-induced insulin 
release (131, 132). 
Individuals suffering from PC deficiency exhibit a variety of clinical and biochemical 
abnormalities including metabolic acidosis, hypotonia, delayed physical and mental 
development and seizures. Those who survive are severely retarded (114, 117, 133). 
Currently the recommended dietary treatment for PC deficiency offers limited options since a 
high-fat diet would increase ketoacidosis, while a high carbohydrate diet would exacerbate 
lactic acidosis (134). 
 
2.2.3.3 Propionyl-CoA carboxylase (PCC, EC 6.4.1.3) 
See section 2.1.4 for information about PCC and the effects of PCC deficiency. 
 
2.2.3.4 3-Methylcrotonyl-CoA carboxylase (MCC, EC 6.4.1.4) 
MCC catalyzes the fourth step of the leucine catabolic pathway (Figure 2, enzyme 3) by 
carboxylating 3-methylcrotonyl-CoA to form 3-methylglutaconyl-CoA (Figure 9) in a reversible 
ATP-dependent reaction using bicarbonate as the source of the carboxyl group (65). MCC 
consists of a larger α subunit, which covalently binds biotin, and a smaller β subunit (54). The 
MCCA and MCCB structural genes have been mapped to 3q25-q27 and 5q12-q13.1 and 
have 19 and 17 exons, and have a size of 80 and 61 kDa, respectively (116, 135, 136). MCC 
is predominantly localized to the inner membrane of mitochondria and is highly expressed in 
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kidney and liver (65). The α and β subunits are synthesized in the cytoplasm and are 
transported into the mitochondria by means of a signal peptide (137, 138). 
Recently, the first recombinant baculovirus expressed MCC has been generated, purified as 
a 500-800 kDa complex and found to be enzymatically active with enzyme characteristics 
similar to those reported for the native enzyme (139). Bovine MCC has a similar size and has 
been shown to be comprised of six heterodimers (140). 
 
Leucine
3-Methylcrotonyl-CoA
3-Methylglutaconyl-CoA
3-Methylcrotonyl-CoA
carboxylase
3-Methylcrotonic acid
3-Methylcrotonylglycine 
3-Hydroxyisovaleric acid
3-Hydroxyisovalerylcarnitine
Acetoacetic acid Acetyl-CoA Mevalonic acid
ATP, HCO3
-
ADP
HOOC – CH2 – C = CH – C – S – CoA
CH3
O
–
=
H3C – C = CH – C – S – CoA
CH3
O
–
=
–
=
–
=
–
=
–
=
 
Figure 9: Degradation pathway of leucine. 3-Methylcrotonyl-CoA is converted to 3-methylglutaconyl-CoA by 
MCC in an ATP and bicarbonate dependent reaction. MCC deficiency leads to the accumulation of abnormal 
metabolites, like 3-methylcrotonic acid, 3-methylcrotonylglycine, 3-hydroxyisovaleric acid and 3-
hydroxyisovalerylcarnitine. ATP, adenosine triphosphate; ADP, adenosine diphosphate; HCO3
-
, bicarbonate; CoA, 
coenzyme A (modified from (116)). 
 
2.2.3.4.1 3-Methylcrotonyl-CoA carboxylase deficiency (MIM 210200 and 210210) 
MCC deficiency is caused either by defects of the MCC enzyme itself or by deficient activity 
of the enzymes involved in the metabolism of its cofactor biotin, i.e. holocarboxylase 
synthetase (HCS) or biotinidase, which cause multiple carboxylase deficiency. Isolated 
biotin-resistant MCC deficiency (also known as methylcrotonylglycinuria) is inherited as an 
autosomal recessive trait (65). The disorder must be distinguished from the biotin-responsive 
multiple carboxylase deficiencies. In isolated MCC deficiency, increased urinary levels of 3-
hydroxyisovaleric acid and 3-methylcrotonylglycine are characteristically found. In multiple 
carboxylase deficiencies additional metabolites which are characteristic of PC and PCC 
deficiencies, e.g. lactic acid, 3-hydroxypropionate and small amounts of methylcitrate are 
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present. Confirmation of the isolated deficiency requires an activity assay of MCC and at 
least one other carboxylase, usually PCC. 
The first case of MCC deficiency was described in a 4.5 months old girl, from 
consanguineous background, that had elevated urinary excretion of 3-hydroxyisovaleric acid 
and 3-methylcrotonylglycine. However, no enzyme activities were measured, and the child 
died in spite of being on a low-leucine diet (141, 142). 
Over 45 cases of isolated MCC deficiency have been clinically described (143-149). Most 
patients are asymptomatic until an episode of acute metabolic crisis following intercurrent 
illness or introduction of a protein-rich diet in early childhood leads to their diagnosis (65). 
Patients presenting with severe symptoms are commonly from consanguineous marriages, 
the clinical symptoms may therefore be due to a different, yet unknown primary disorder. 
Symptoms can include vomiting, opisthotonus, involuntary movements, seizures, muscular 
hypotonia, coma and apnoea. Typical laboratory findings during an acute episode include 
severe hypoglycemia, hyperammonemia, elevated hepatic transaminases, mild metabolic 
acidosis and moderate ketonuria. Patients with MCC deficiency show a persistently high 
urinary excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine, usually in 
combination with a severe secondary carnitine deficiency. In addition, acyl-CoA derivatives 
accumulate and are esterified to acylcarnitine esters. The major abnormal metabolite found 
in blood and urine is 3-hydroxyisovalerylcarnitine (65). 
Patients usually respond to intravenous fluids and cessation of protein feeding and are 
asymptomatic between acute episodes. Some affected subjects have been placed on a 
modestly leucine restricted diet supplemented with oral L-carnitine and glycine to enhance 
detoxification ability of the accumulating toxic metabolites. It seems that the glycine and L-
carnitine detoxification systems are complementary to each other rather than competitive 
(150-153). No comprehensive studies of intellectual and/or developmental outcome have 
been published so far.  
MCC activity in homogenates of cultured skin fibroblasts of patients is usually less than 2 % 
of control values, although 4 patients with activity from 4-12 % of normal have been reported 
(116, 148, 154). To date, many functionally significant mutations in both MCCA and MCCB 
have been reported including missense, nonsense, frame-shift and splice-site mutations 
(116, 135, 136, 149, 155, 156). 
So far, no genotype-phenotype correlation has been found. MCCB E99Q for example was 
detected in a boy that died (157) but also in an adult woman that was asymptomatic (158). 
The same is true for other mutations that have been described in both severe and 
asymptomatic cases (146, 156, 159, 160). Also no correlation between the level of residual 
enzyme activity and clinical presentation has been observed. 
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Before the advent of tandem mass spectrometry (TMS) technology and the introduction of 
newborn screening (NBS) programs in the late 1990s, it was thought that MCC deficiency 
was an extremely rare metabolic disorder. However, the introduction of TMS based NBS 
programs in North America (158, 161-163), Europe (146, 164, 165) and Australia (42) 
showed that MCC deficiency is the most frequent organic aciduria detected with an overall 
frequency of around 1:50'0000. Comparative analysis of case reports with NBS data implied 
that very few individuals (<10 %) develop symptoms (146). This together with a number of 
affected siblings of symptomatic patients that have been clinically normal (166-168), 
suggests that the genotype at the MCC locus is not the sole determining factor in the 
manifestation of the disease and that MCC deficiency represents a complex monogenetic 
trait (65) with a functionally mild expression and low clinical penetrance.  
 
Furthermore, the clinical phenotype is highly variable: some patients present in the neonatal 
period with one or more of the above mentioned symptoms and have a poor outcome despite 
treatment (157, 169, 170). Others are asymptomatic siblings and adults detected in family 
studies or due to positive newborn screening findings in their unaffected babies (146, 158, 
161). A similar finding can be made in isovaleric acidemia (IVA, section 2.1.2), this disease is 
caused by mutations in the gene coding for isovaleryl-CoA dehydrogenase. The clinical 
penetrance of IVA is much greater than for MCC deficiency however there is also a mutation 
often detected by NBS that leads to a biochemical phenotype (excretion of abnormal 
metabolites) but does not produce a clinical phenotype. 
 
2.2.3.4.2 Newborn Screening and 3-methylcrotonyl-CoA carboxylase deficiency 
The marker for screening for MCC deficiency is 3-hydroxyisovalerylcarnitine, a member of 
the C5OH carnitines. Another C5OH found in humans is 2-methyl-3-hydroxybutyrylcarnitine. 
These isomeric carnitines (Figure 10) can only be distinguished by HPLC/MS, not by MS/MS 
(171-173). As MS/MS is the standard method used for NBS, elevated levels of C5OH can be 
found in patients having various defects including 3-methylcrotonyl-CoA carboxylase 
deficiency, 3-hydroxy-3-methylglutaryl-CoA lyase deficiency, 2-methylacetoacetyl-CoA 
thiolase deficiency, 3-methylglutaconyl-CoA hydratase deficiency as well as biotinidase 
deficiency, holocarboxylase deficiency and dietary biotin deficiency (174). Screening for 
C5OH may be warranted when considering the wide range of significant conditions that can 
be identified. However there seems to be a need for a proper research study evaluating the 
benefits of screening for this metabolite (Bridget Wilcken, personal communication). 
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3-Hydroxyisovalerylcarnitine 2-Methyl-3-hydroxybutyrylcarnitine  
Figure 10: two isomeric C5OH carnitines found in various diseases. These two isomeric carnitines can only 
be distinguished by HPLC/MS and not by MS/MS, the method used in routine NBS programs. 
 
Currently MCC deficiency is still part of expanded NBS programs in Australia, Austria, 
Canada, Denmark, the Netherlands, New Zealand and the US (40, 175, 176). However, 
controversy is starting to mount around the continued inclusion of MCC deficiency in NBS 
programs. A recent analysis of NBS in Bavaria in 677‟852 neonates revealed 8 newborns 
and 6 relatives with MCC deficiency (146). The individuals were all asymptomatic or had 
benign phenotypes. Calculated risk of death has been estimated to be at maximum 
1:8‟500‟000, the risk of clinical symptoms 1:1‟200‟000 (146). 
Up to now it is impossible to stratify risk precisely in babies diagnosed for MCC deficiency by 
NBS to suffer from clinical symptoms, however it is important to adopt appropriate 
management protocols and not to over-react and cause more harm than good (177, 178). In 
Germany the low ratio of benefit to harm has resulted in the decision to exclude MCC 
deficiency from NBS in most federal states. Therefore, MCC deficiency is an example of the 
ongoing debate arising from the inclusion of potentially asymptomatic conditions, which 
generates a psychological burden for afflicted families and a financial burden for health care 
systems (41, 146, 156). 
In the past, several disorders were screened for and treated but were found to be benign 
after all. Examples include Histidinemia (41, 179-183) or Hydroxyprolinemia (41, 184-187). 
 
2.2.3.4.3 Aims of the 3-methylcrotonyl-CoA carboxylase project 
When I started my PhD, the aim was to investigate the size of the active human MCC 
protein, mitochondrial import of the subunits and to describe interesting mutations in detail. 
The size of the active human MCC complex has been published by Chu et al. (139) and 
mitochondrial import of the subunits has been investigated by Stadler et al. (138). Therefore 
we focused on describing an interesting mutation we found in one of our MCC patients. 
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2.2.4 Cobalamin (vitamin B12) 
Vitamin B12 (cobalamin) is the largest and chemically most complex of all the vitamins (Figure 
11). It is thought to have originated some 3 billion years ago when no oxygen was present 
yet and other molecules carried out oxidation reactions. The metal-ions in enzymes carrying 
out these reactions included nickel, iron, manganese and cobalt. With the advent of oxygen, 
sulphur was oxidized and subsequently formed insoluble complexes with these metal ions. 
As a result many enzymes replaced their metal-ions by zinc or copper. Cobalamin can 
therefore be regarded as a legacy of ancient times (188). 
 
 
Figure 11: Structure of cobalamin (vitamin B12). The cobalt ion is in the middle of a corrin ring, R represents 
the various side-chains (Methyl-, 5‟-Deoxyadenosyl-, Hydroxy-, Cyano- etc.). 
 
Nowadays, cobalamin is synthesized only by certain bacteria (189, 190) and is subsequently 
concentrated mainly in the bodies of higher organisms. The main dietary sources of the 
vitamin are therefore of animal origin. Some plant foods like edible algae (e.g. Porphyra sp. 
commonly known as nori) also contain large amounts of cobalamin. For a long time the 
source of algal cobalamin remained a matter of controversy, however, it has been shown that 
algae do not synthesize it themselves, they acquire it through a symbiotic relationship with 
bacteria (191, 192). Whereas the algal cobalamin seems to be bioavailable to mammals, the 
one produced by certain cyanobacteria like Spirulina seems to be inactive in mammals (193). 
Due to the limited bioavailability, the uptake and recycling of cobalamin is highly efficient. 
The recommended daily allowance (RDA) is the lowest of all vitamins and is set at 
2.4 µg/day in adults (194). It is important to note that during cooking or microwave heating, 
considerable amounts of cobalamin are destroyed (195). The same is true during 
fermentation processes (e.g. in the production of yoghurt and cheese from milk) (196). 
Once taken up by the body, cobalamin is accumulated and stored in the liver; therefore an 
adult human's diet may be cobalamin deficient for many months to years before developing 
clinical symptoms. 
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In mammals, cobalamin functions as coenzyme for two enzymes. In the form of 
methylcobalamin (MeCbl) for the cytosolic methionine synthase (MS; EC 2.1.1.13, see 
section 2.2.4.1) and in the form of 5‟-deoxyadenosylcobalamin (adenosylcobalamin, AdoCbl) 
for the mitochondrial methylmalonyl-CoA mutase (EC 5.4.99.2). 
Recent findings suggest that cobalamin in the form of thiolatocobalamins may act as an 
intracellular antioxidant and may therefore play an important role in cell survival during 
inflammation (197). 
 
2.2.4.1 Cobalamin uptake and metabolism 
Dietary cobalamin enters the stomach mostly bound to animal proteins. Pepsin and 
hydrochloric acid cleave the animal protein, thus releasing free cobalamin. Most of the free 
cobalamin is subsequently bound to R-protein, a protein released from the salivary glands 
and the parietal cells in the stomach. Another protein, “intrinsic factor” is also secreted by the 
stomach; however, its binding to cobalamin is weak in the presence of R-protein. In the 
duodenum, pancreatic enzymes degrade the cobalamin-R-protein complexes releasing free 
cobalamin. This is when cobalamin binds to intrinsic factor. The resulting cobalamin-intrinsic 
factor complex remains undisturbed until the distal part of the ileum where it is taken up by 
epithelial cells via the intrinsic factor receptor complex, containing the proteins cubilin and 
amnionless, through receptor-mediated endocytosis. Within the epithelial cells, cobalamin is 
bound to transcobalamin I & II (transcobalamin III has been shown to be identical to 
transcobalamin I, the only difference is the charge, presumably due to a different 
glycosylation pattern; Ralph Carmel, personal communication), these complexes enter the 
bloodstream and are distributed throughout the body (Figure 12). 
More than 70 % of the cobalamin in the blood circulates bound to transcobalamin I, a protein 
that has been shown to be identical with R-protein, the function of this complex is still 
unknown (198). On the plasma membrane of target cells the cobalamin-transcobalamin II 
complex binds to the transcobalamin receptor (Figure 16; TCblR) and is internalized by 
receptor-mediated endocytosis (199, 200). 
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Figure 12: Cobalamin metabolism and corresponding causes of deficiency. 
Causes of cobalamin deficiency are shown in blue. The metabolic pathway starts when (1) dietary cobalamin 
(Cbl), obtained through animal foods, enters the stomach bound to animal proteins (P). (2) Pepsin and 
hydrochloric acid (HCl) in the stomach sever the animal protein, releasing free cobalamin. Most of the free 
cobalamin is then bound to R-protein (R), which is released from the salivary and parietal cells. Intrinsic factor (IF) 
is also secreted in the stomach, but its binding to cobalamin is weak in the presence of R-protein. (3) In the 
duodenum, dietary cobalamin bound to R-protein is joined by cobalamin-R-protein complexes that have been 
secreted in the bile. Pancreatic enzymes degrade both biliary and dietary cobalamin-R-protein complexes, 
releasing free cobalamin. (4) Cobalamin then binds to intrinsic factor. The cobalamin-intrinsic factor complex 
remains undisturbed until the distal 80 cm of the ileum, where (5) it attaches to mucosal cell receptors (cubilin) 
and is taken up. Inside the cell cobalamin is bound to transcobalamin I-III (TCI-TCIII). Transcobalamin II, although 
it represents only a small fraction (about 10 %) of the transcobalamins, is the most important as it is able to 
deliver cobalamin to all cells in the body. The cobalamin is subsequently transported systemically via the portal 
system. (6) Within each cell, the transcobalamin II-cobalamin complex is taken up by means of endocytosis and 
the cobalamin is liberated and then converted enzymatically into its 2 coenzyme forms, methylcobalamin and 
adenosylcobalamin (this process is shown in greater detail in Figure 16). 
*Nitrous oxide, a general anesthetic, causes multiple defects in cobalamin use, most of which are intracellular and 
clinically relevant only in people who have low or borderline-low serum cobalamin levels (201, 202). 
© (203), illustration by Cristine Kenney. Copied under license from Access Copyright. Further reproduction 
prohibited. 
It has been shown that cubilin forms a complex with amnionless in order to import cobalamin (204). 
Further it was shown that TCI and TCIII are the same protein differing only in the glycosylation pattern. 
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Once inside the cell, cobalamin is processed by various steps leading to the formation of 
methylcobalamin (MeCbl) and 5‟-deoxyadenosylcobalamin, referred to as 
adenosylcobalamin (AdoCbl) (Figure 16). 
Methylcobalamin, is a cofactor for methionine synthase (MS, EC 2.1.1.13), a cytosolic 
enzyme that catalyzes the conversion of homocysteine to methionine (Figure 13). The 
reaction requires N5-methyltetrahydrofolate and is important for the supply of 
tetrahydrofolate, needed for the synthesis of RNA and DNA; the synthesis of S-
adenosylmethionine, required for a multitude of methylation reactions; and for the catabolism 
of the toxic amino acid homocysteine. Methionine synthase is composed of four distinct 
domains, a cobalamin binding domain, a homocysteine binding domain, a C-terminally 
located activation domain and tetrahydrofolate binding domain. 
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Figure 13: Degradation pathway of Homocysteine. Methionine synthase converts homocysteine to methionine 
in a cobalamin dependent reaction using N
5
-tetrahydrofolate as a methyl-donor. 
 
MS utilizes enzyme-bound cob(I)alamin to abstract a methyl group from N5-
methyltetrahydrofolate to generate tetrahydrofolate and methylcob(III)alamin. The methyl 
group is subsequently transferred to the thiol group of homocysteine to produce methionine 
and regenerate cob(I)alamin. The detailed reaction is depicted in Figure 14. 
 
A)
B)
cob(I)alamin + N5-methyltetrahydrofolate           methylcob(III)alamin + tetrahydrofolate
methylcob(III)alamin + homocysteine           cob(I)alamin + methionine
homocysteine + N5-methyltetrahydrofolate           methionine + tetrahydrofolateNet:  
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Figure 14: Detailed reaction scheme of the action Figure 15: The catalytic cycle and reactivation 
of methionine synthase. Reproduced with permission of methionine synthase by methionine  
from (205), www.biochemsoctrans.org. reductase (grey). With permission from (206). 
 
To some extent cob(I)alamin is oxidized to cob(II)alamin, rendering MS inactive. In this case 
reactivation of MS requires reductive methylation of cob(II)alamin, a process involving 
methionine synthase reductase (MSR) and methyl transfer from S-adenosylmethionine. 
Reducing equivalents for the reduction of cob(II)alamin catalyzed by MSR are derived from 
NADPH oxidation and are delivered via the flavin adenine dinucleotide and flavin 
mononucleotide redox centers of MSR (Figure 15) 
 
The second cobalamin-containing coenzyme adenosylcobalamin is a cofactor for 
methylmalonyl-CoA mutase (MUT), an enzyme localized within mitochondria. MUT is 
essential for the conversion of methylmalonyl-CoA to succinyl-CoA in the degradation of 
various BCAA, odd-chain fatty acids, cholesterol as well as thymine and uracil (Figure 4, 
enzyme 3). This reaction is described in more detail in section 2.1. 
 
2.2.4.2 Inherited and acquired cobalamin deficiencies 
Vitamin B12 deficiency can be caused by primary factors such as veganism or by a multitude 
of genetic disorders (207). The latter can be due to defects in absorption, transport, cellular 
uptake and intracellular processing of cobalamin. 
Absorption defects include defects in intrinsic factor (203, 208), R-protein (209) or cubilin 
(210). Recently the proteins amnionless and megalin were reported to be associated with 
cubilin and to be involved in cobalamin uptake (211-214). Transport defects include defects 
in transcobalamin I (215-217), transcobalamin II (218-220). Cellular uptake occurs via 
receptor-mediated endocytosis by the transcobalamin-receptor (200). 
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Intrinsic factor deficiency and Imerslund-Gräsbeck syndrome (deficiency in cubilin or 
amnionless) have been shown to cause cobalamin deficiency in children and lead to 
megaloblastic anemia that may end up fatal if untreated (221). In elderly patients, cobalamin 
deficiency can be caused by pernicious anemia, an autoimmune disease characterized by 
the destruction of the gastric mucosa (222). Under these circumstances, gastric secretions 
are neutral to slightly acidic and contain little or no intrinsic factor (223). Pernicious anemia is 
further associated with many autoimmune disorders like vitiligo or Sjögren's syndrome (224). 
Transcobalamin I deficiency has been shown to be difficult to distinguish from cobalamin 
deficiency. Furthermore, affected patients have normal methylmalonic acid and 
homocysteine levels, making lifelong cobalamin treatment unnecessary (198). 
Deficiency of transcobalamin II can lead to fatality in early infancy but can be treated with 
parenteral cobalamin. Diagnosis can be difficult as plasma cobalamin levels are normal 
because most of the cobalamin is bound to transcobalamin I. Symptoms include 
megaloblastic anemia, pancytopenia, failure to thrive and eventually neurological symptoms 
(225, 226). 
So far no patients with defects in the transcobalamin-receptor have been reported, however 
the phenotype would most likely share similarities with transcobalamin II deficiency. 
Defects in uptake and transport of cobalamin are expected to also cause homocystinuria, 
however this finding is not explicitly mentioned in the above mentioned publications. It has 
even been shown that in some patients with a severe transcobalamin II deficiency, plasma 
homocysteine and amino acid levels were within normal limits (226). 
 
To date, intracellular defects of cobalamin metabolism are divided into eight different 
complementation groups, each of which corresponds to a defect in one gene (Figure 16) (75, 
227-234). 
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Figure 16. Intracellular cobalamin metabolism and its defects. 
Cobalamin bound to transcobalamin II enters the cell by means of lysosome-mediated endocytosis via 
transcobalamin-cobalamin receptor (TCblR) and is released by proteolysis. Export from the lysosome into the 
cytoplasm is defective in patients with the cblF defect. The steps in the cytosol after lysosomal release are still 
unclear but are defined by the complementation groups cblC and cblD. In addition, the exact form of cobalamin at 
this stage is unclear (as indicated by “Cblx”). In the cytoplasm, cobalamin is reductively methylated by methionine 
synthase reductase (cblE) to methylcobalamin, the cofactor for methionine synthase (cblG). In mitochondria, 
cobalamin is converted to adenosylcobalamin, the cofactor for methylmalonyl-coenzyme A (CoA) mutase (MUT), 
by cobalamin adenosyltransferase (cblB). The exact role of the protein associated with the cblA complementation 
group is unclear. The cblD protein (MMADHC) constitutes a branch point between the cytosolic and mitochondrial 
pathways, leading to three phenotypes: cblD-methylmalonic aciduria, cblD-homocystinuria and the combination of 
these. 
Figure modified from (75). 
 
2.2.4.3 Methylmalonic acid and methylmalonic aciduria 
These parts are discussed in detail in section 2.1.5. 
 
2.2.4.4 Homocysteine and hyperhomocysteinemia 
Homocysteine, a sulphur-containing amino acid, is not obtained with the diet; it is produced 
in the cells as an intermediate in one-carbon metabolism. Methionine is converted to S-
adenosylmethionine (SAM) by S-adenosylmethionine synthase in an ATP-dependent 
reaction. SAM acts as a methyl-donor for many methylation reactions within the cells forming 
S-adenosylhomocysteine (SAH). S-adenosylhomocysteine hydrolase releases the adenosine 
forming homocysteine (Figure 17). As homocysteine is potentially toxic, two mechanisms 
help to keep intracellular levels of homocysteine low (<10 µmol/l); a cellular export 
mechanism and intracellular catabolism of homocysteine (235, 236). A variety of 
homocysteine species exist in human plasma such as protein (albumin)-bound, free 
circulating disulfide and sulfhydryl forms (237). Current laboratory methods detect the 
presence of all three forms and report this as total homocysteine concentration. 
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Intracellular homocysteine metabolism represents an intersection of two pathways: 
remethylation to methionine by methionine synthase, a reaction requiring folate and vitamin 
B12 (or betaine in an alternative reaction catalyzed by betaine-homocysteine 
methyltransferase, although this pathway is only present in the liver (238)) and 
transsulfuration to cystathione, which requires pyridoxal-5‟-phosphate (vitamin B6). The two 
pathways are coordinated by S-adenosylmethionine (SAM), which can act as an inhibitor of 
the methylenetetrahydrofolate reductase (MTHFR) and as an activator of cystathionine β-
synthase (Figure 17). 
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Figure 17: Homocysteine represents an intersection of two pathways: remethylation to methionine by 
methionine synthase, a reaction requiring folate and vitamin B12; and transsulfuration to cystathionine requiring 
vitamin B6. The reaction betaine dependent conversion of homocysteine to methionine and dimethyl-glycine 
carried out by betaine-homocysteine methyltransferase is only present in liver and kidney and represents a 
possible treatment option for hyperhomocysteinemia in these organs. SAM: S-adenosylmethionine, SAH: S-
adenosylhomocysteine, THF: tetrahydrofolate. 
 
Homocysteine metabolism is nutritionally regulated: while the amount of homocysteine 
degraded via the transsulfuration pathway decreases when the subjects are on a methionine 
restricted diet, excess dietary methionine leads to degradation of homocysteine via the 
transsulfuration pathway with the levels falling below baseline (10 µmol/l) (239). 
This coordination seems to be achieved by two mechanisms, first SAM can act as an 
inhibitor of MTHFR as well as an activator of cystathionine β-synthase. Thereby, SAM 
suppresses the synthesis of N5-Methyl-THF, an important substrate for remethylation, while 
at the same time promoting the initial reaction of transsulfuration. Secondly, the synthesis of 
SAM is regulated by two isoforms of S-adenosylmethionine synthases, one with a high 
affinity for methionine, the other with a low affinity for methionine. The two enzymes function 
at different methionine concentrations and have a different rate at which they can synthesize 
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SAM (240). Additionally, SAM seems to be regulated by glycine methyltransferase, an 
enzyme involved in the methyl-transfer from SAM to glycine forming methylglycine. This 
enzyme is abundant in the liver and is strongly inhibited by N5-methyltetrahydrofolate. Thus, 
beside intracellular methionine, N5-methyltetrahydrofolate also participates in the regulation 
of intracellular SAM concentrations (241). Part of the intracellular regulation of homocysteine 
metabolism is depicted in Figure 18. 
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Figure 18: The regulation of intracellular homocysteine concentration: Homocysteine is a substrate for 
methionine synthase forming methionine in a vitamin B12-dependent reaction. Methionine again is a precursor of 
SAM, an essential methyl-donor. High levels of SAM exert inhibitory effects on MTHFR and at the same time 
activate the B6-dependent cystathionine β-synthase. SAM itself is converted to S-adenosylhomocysteine (SAH) 
by transfering its methyl group to various substrates. Reactions carried out by multiple methyltransferases. As 
SAH is a potent inhibitor of most methyltransferases, glycine methyltransferase is inhibited by high levels of N5-
methyltetrahydrofolate, making sure that the ratio of SAM/SAH remains high to assure methylation. 
 
Genetic defects in one of these steps or nutritional deficiency of one or more vitamins crucial 
for homocysteine metabolism can lead to hyperhomocysteinemia.  
Hyperhomocysteinemia is caused by accumulation of homocysteine and is diagnosed by 
elevated levels of homocysteine in plasma and urine. The various forms of the disease can 
be categorized due to cause, prevalence and severity. 
Defects in intracellular cobalamin metabolism leading to hyperhomocysteinemia include the 
cblF, cblC and cblD defect that lead to a combination of methylmalonic aciduria and 
homocystinuria and the cblE and cblG defects that lead to isolated homocystinuria. The 
clinical and biochemical phenotype of cblE and cblG patients is virtually identical. Affected 
patients suffer from severe developmental delay, ataxia, neonatal seizures and blindness. 
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They excrete high amounts of homocysteine while levels of methylmalonic acid are normal 
(72). 
Severe hyperhomocysteinemia with levels up to 400 µmol/l is also caused by defects in 
cystathionine β-synthase (CBS) or MTHFR (242-244). In CBS deficiency the transsulfuration 
pathway is severely affected, thus the rate of methionine synthesis is increased leading to an 
increase in intracellular concentration of SAM. High levels of SAM cause feedback inhibition 
of MTHFR, thereby blocking both pathways involved in the degradation of homocysteine 
(245, 246). Clinical phenotypes of CBS deficiency also include ectopia lentis due to 
disruption of disulfide bonds in cysteine-rich fibrillin and marfanoid habitus due to 
abnormalities in collagen crosslinking (244, 247). 
In MTHFR deficiency, homocysteine can be degraded solely by the transsulfuration pathway. 
However, low intracellular methionine levels lead to a decrease in intracellular SAM 
concentration lowering the efficiency of the transsulfuration pathway. As SAM is necessary 
for polyamine synthesis and for the methylation of numerous essential cell components such 
as phospholipids, methyl-accepting proteins, CpG islands in DNA, adrenergic, dopaminergic 
and serotoninergic molecules, SAM deficiency leads to a multitude of disorders. Furthermore 
SAM also feeds the transsulfuration pathway converting homocysteine to glutathione, the 
main cellular antioxidant required for detoxification of various cellular compounds and for the 
scavenging of free radicals (248). 
Low intracellular SAM concentrations have been shown to lead to increased susceptibility to 
steatosis and oxidative liver injury, spontaneous development of steatohepatitis and 
hepatocellular carcinoma (249). 
A genetic defect in any of the enzymes required for the synthesis of methyl-cobalamin, the 
cofactor of methionine synthase, leads to low intracellular SAM concentrations. Thus less 
homocysteine is being synthesized from SAM. The hyperhomocysteinemia resulting from 
impaired remethylation of homocysteine may not be as severe as that observed in MTHFR 
deficiency because transsulfuration is more active catabolizing homocysteine (250). The 
various defects leading to hyperhomocysteinemia are shown in Figure 18. 
Mild hyperhomocysteinemia is caused by dietary folate or B12 deficiency or by moderate 
enzyme defects such as the common MTHFR polymorphism c.C677T (251). 
A third phenotype is the post-methionine load hyperhomocysteinemia where total 
homocysteine increases only after a methionine load. Defects accounting for this 
phenomenon include dietary B6 deficiency or a heterozygosity for a CBS defect (246). 
Increasing age, impaired renal function, high levels of plasma creatinine, smoking, coffee 
consumption, alcoholism and certain drugs can also cause moderate increases in plasma 
homocysteine levels (252). 
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Hyperhomocysteinemia is associated with increased risk of developing a multitude of 
diseases including vascular diseases (253), arthrosclerosis (254), Alzheimer's disease (AD) 
(255) and end-stage renal disease (256). 
As homocysteine metabolism in endothelial cells of human blood vessels relies exclusively 
on folate and vitamin B12-dependent remethylation (257), the cardiovascular system is 
particularly sensitive to elevated levels of homocysteine. However, randomized clinical trials 
have shown that while vitamin supplementation substantially lowers the levels of circulating 
homocysteine, the outcome in the secondary prevention of cardiovascular disease or 
dementia is not improved (258). 
Furthermore experimental evidence suggests that homocysteine can induce DNA damage in 
the CNS and may therefore play a role in ageing, cognitive decline and various forms of 
dementia including AD (259). DNA damage may be due to increased formation of reactive 
oxygen species (ROS). Intracellular homocysteine can reduce metal ions (e.g. Cu2+) in a 
reaction that promotes the formation of reactive oxygen species (ROS). High concentrations 
of ROS can induce synaptic failure and may induce cellular changes associated with AD 
(260). 
The underlying mechanism of homocysteine-induced end-stage renal disease is not fully 
understood but protein-bound homocysteine may reduce the glomerular filtration rate thereby 
further increasing circulating levels of homocysteine (261). 
 
Treatment of genetic defects leading to hyperhomocysteinemia is limited. Depending on the 
nature of the defect, various forms of treatment can lower homocysteine levels and improve 
the outcome (262). 
Treatment options are as follows (see Figure 18 for details): 
 
- folates such as folic and folinic acid help maximize residual MTHFR activity 
- the cofactor riboflavin can enhance the residual activity of MTHFR 
- N5-methyltetrahydrofolate can replace the missing product of MTHFR 
- pyridoxine can activate cystathionine β-synthase 
- OH- or Me-cobalamin can support MS or to help maximize residual MS activity 
- betaine to support betaine-homocysteine methyltransferase 
- methionine to replenish methionine, SAM and carnitine 
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2.2.4.5 Aims of the cobalamin project 
The aim of this part of my thesis was to clone the wildtype and mutant cDNAs of various 
proteins involved in intracellular cobalamin metabolism. These constructs were transfected 
into immortalized fibroblasts from subjects with a defect in intracellular cobalamin metabolism 
as well as controls. By doing so, we investigated the effect of the various wildtype and 
mutant cDNAs on the synthesis of cobalamin cofactors and their implication on disease. 
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ABSTRACT 
3-Methylcrotonyl-CoA carboxylase (MCC) deficiency is an autosomal recessive disorder of leucine catabolism. 
MCC is a heteromeric mitochondrial enzyme composed of biotin-containing α (MCCA) and smaller β (MCCB) 
subunits encoded by MCCA and MCCB, respectively. We report studies of the c.1054G→A mutation in exon 11 
of MCCB detected in the homozygous state in a patient with MCC deficiency. Sequence analysis of MCCB cDNA 
revealed two overlapping transcripts, one containing the normal 73 bp of exon 11 including the missense mutation 
c.1054G→A (p.G352R), the other with exon 11 replaced by a 64 bp sequence from intron 10 (cryptic exon 10a) 
that maintains the reading frame and is flanked by acceptable splice consensus sites. In expression studies, we 
show that both transcripts lack detectable MCC activity. Western blot analysis showed slightly reduced levels of 
MCCB using the transcript containing the missense mutation, whereas no MCCB was detected with the transcript 
containing the cryptic exon 10a. Analysis of the region harboring the mutation revealed that the c.1054G→A 
mutation is located in an exon splice enhancer sequence. Using MCCB minigene constructs to transfect MCCB-
deficient fibroblasts, we demonstrate that the reduction in utilization of exon 11 associated with the c.1054G→A 
mutation is due to alteration of this exon splice enhancer. Further, we show that optimization of the weak splice 
donor site of exon 11 corrects the splicing defect. To our knowledge, this is the first demonstration of a point 
mutation disrupting an exon splice enhancer that causes exon skipping along with utilization of a cryptic exon. 
 
Accurate and efficient removal of introns from pre-mRNA is essential for gene expression. 
The information present in the consensus splice-site signals, the 5' splice-site, branch site, 
and 3' splice-site, is necessary but not always sufficient to define exon-intron boundaries (1, 
2). On average, these signals appear to provide about half of the information required for 
exon and intron recognition in human transcripts (3). Sequences flanked by consensus 
splice-site sequences but not known to be retained in mature transcripts are common in 
introns. Some may be “cryptic exons” that for unknown reasons are not normally included in 
mature mRNAs; others may be “true” exons that have not been recognized because they are 
alternatively spliced in some developmental or tissue-specific fashion (1, 4, 5). 
Additional cis-acting sequence elements that function as splicing enhancers and silencers 
exist in the genome (6). Exon splice enhancers (ESEs)2 are short sequences within exons 
that augment exon recognition and the control of alternative splicing (1). ESEs bind 
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serine/arginine-rich (SR) proteins, a family of essential splicing proteins that activate splicing 
by defining exons and recruiting the splicing machinery to the adjacent intronic splice 
consensus sequence (6-8). ESEs appear to be common and are present in most, if not all, 
exons including constitutive exons (6, 9). Unlike transcriptional enhancers, ESEs function in 
a strongly position-dependent manner, enhancing splicing when present downstream of a 3' 
splice-site or upstream of a 5' splice-site. Other cis-acting sequences, often in introns, 
repress exon recognition (6, 10). In some instances, ESEs appear to compensate for “weak” 
5' or 3' splice signals in introns. Strengthening of the splice consensus sites of an enhancer-
dependent exon by site-directed mutagenesis may eliminate dependence on the enhancer 
(8, 10). 
Single nucleotide substitutions in the coding regions of genes are the most commonly 
recognized type of mutation underlying inherited human diseases (11). The molecular 
pathophysiology of nonsense mutations results from a combination of premature termination 
of translation and nonsense-mediated mRNA decay (NMD) (12, 13). The NMD pathway is 
activated by nonsense mutations (or frame-shifting deletions or insertions) that occur 5' of the 
last exon-intron junction and minimizes the potential for problems caused by truncated 
proteins by reducing the abundance of the abnormal transcript (12, 13). The deleterious 
effects of missense mutations are usually attributed to their effects on protein stability, 
folding, or function (14), whereas synonymous mutations are often assumed to have no 
pathophysiologic consequences. Recently, our understanding of the potential pathological 
effects of single nucleotide substitutions has been expanded to include alterations that 
inactivate ESEs causing exon skipping (10, 15-17). The importance of considering the 
possibility of RNA-processing phenotypes in the analysis of the consequences of mutations 
is emphasized by the growing list of exonic variations that alter RNA-processing and thereby 
cause or modify disease (see the list of 34 missense and 26 “silent” point mutations causing 
exon skipping reviewed in Ref. 6). 
3-Methylcrotonyl-CoA carboxylase (MCC, EC 6.4.1.4) is a heteromeric mitochondrial enzyme 
composed of biotin-containing α subunits and smaller β subunits, encoded by MCCA 
(MCCC1; Mendelian Inheritance in Man (MIM) 609010) and MCCB (MCCC2; MIM 609014), 
respectively (18). Mutations in these genes can cause isolated MCC deficiency (MIM 210200 
and 210210), a disorder of leucine catabolism inherited as an autosomal recessive trait with 
a variable phenotype that ranges from neonatal-onset with severe neurological involvement 
to asymptomatic adults (11, 18, 19). Introduction of tandem mass spectrometry to newborn 
screening has resulted in a large increase in the number of inborn errors that can be 
detected, including several amino acidemias and organic acidurias. This technique has 
shown MCC deficiency to be one of the more frequently detected organic acidurias with an 
overall frequency of ~1:50'000 and a mainly mild phenotype (19, 20). 
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Here we report detailed studies of a missense mutation (c.1054G→A, p.G352R) in exon 11 
of MCCB that disrupts an ESE and causes MCC deficiency by utilization of a cryptic exon 
instead of the normal MCCB exon 11. The patient in which this mutation was detected 
(MCC019) is the child of a consanguineous union and presented at 7 months with failure to 
thrive (19). 
 
EXPERIMENTAL PROCEDURES 
Cell Cultures and Carboxylase Assays - Skin fibroblasts were cultured in Dulbecco‟s 
(transfected cells) or Earl‟s minimal essential medium supplemented with 10 % fetal calf 
serum, 2 mM L-glutamine, and antibiotics. To be able to sequence unstable transcripts, NMD 
was inhibited by adding emetine (100 µg/ml) in the culture medium 10 h before harvesting 
the cells (21). Activities of MCC and propionyl-CoA carboxylase (PCC) were assayed in 
fibroblast homogenates by measuring the incorporation of [14C]bicarbonate into acid non-
volatile products with established methods (22). 
Mutation Analysis by RT-PCR and Genomic PCR - We extracted RNA and genomic DNA 
from cultured fibroblasts using RNA and DNA isolation kits from Qiagen and performed RT-
PCR using 2-5 µg of total cellular RNA with the cDNA cycle kit (Invitrogen) following the 
manufacturer‟s instructions. All PCR reactions (50 µl) contained primers (100 ng each), 
standard PCR buffer (Invitrogen), dNTPs (200 µM), and Taq polymerase (2.5 units; 
Invitrogen). The sequences of all primers are listed in Supplementary Table 1. 
Construction of Wild-type and Mutant MCCB Expression Vectors - To introduce the 
c.1054G→A mutation and the transcript containing the cryptic exon (exon 10a) instead of 
exon 11, we amplified cDNA of patient MCC019 with primers DV4498 and DV4503 and 
subcloned the PCR products into the pTracer-MCCB-wild-type construct (18) by using the 
BstEII and SfiI sites. 
MCCB Minigene Constructs - To examine splicing between exons 9 and 12 of the MCCB 
gene, we constructed an MCCB minigene by modifying a vector (pBK-RSV-OAT), which had 
previously been shown to function as an in vivo splicing template (12). First a multiple cloning 
site was introduced between the XbaI and the PstI sites of the vector. Then an 8.9 kb 
fragment containing the genomic DNA sequence between the 3' end of exon 9 (DV5050) and 
the 5' end of exon 12 (DV5049) of MCCB was amplified from genomic DNA of patient 
MCC019. This sequence was now introduced into the multiple cloning site at the SpeI and 
SacI sites (see Fig. 3a). 
To optimize the donor splice-site of MCCB intron 11 (CAGgtataa), we used site-directed 
mutagenesis to change it into the consensus donor sequence (CAGgtaagt) (see Fig. 3a). To 
do this, overlapping forward (DV5111) and reverse (DV5112) primers containing both the 
c.1054G→A mutation and an optimized intron 11 donor splice-site (c.1072+4 taa→agt) were 
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designed. Primer DV5111 was used with a reverse primer in intron 11 (DV5094), producing a 
1952 bp genomic fragment containing a XmaI site. Primer DV5112 was used with a forward 
primer in intron 10 (DV5110), amplifying a 1381 bp genomic fragment containing a XcaI site. 
These two PCRs were combined and amplified by using the outer primers DV5110 and 
DV5094, producing a 3233 bp genomic fragment containing both the c.1054G→A mutation 
and an optimized donor splice-site of intron 11. This fragment was subcloned into pBK-
MCCB-G352R using the XcaI and XmaI sites to obtain the pBK-MCCB-G352RΔss construct. 
Similarly, to introduce the wild-type sequence, we amplified a 3233 bp genomic fragment 
from control DNA and subcloned it into the pBK-MCCB-G352R construct. We verified that all 
the inserts and constructs had the indicated changes and stayed in-frame by sequencing all 
the exons and flanking intronic sequences. 
Transfections - For expression studies, the constructs were transiently transfected into an 
immortalized MCCB-deficient reference cell line by electroporation as described (19). The 
reference cell line originates from skin fibroblasts of a patient homozygous for MCCB Q43X, 
shows no detectable MCC activity, and does not express detectable MCCB protein. We 
harvested the cells 48 h after transfection and assayed for MCC and PCC activities. 
Protein Extraction and Western Blot - Cell lysates were prepared by harvesting confluent 
fibroblasts from a 75 cm2 flask by trypsinization. The cells were washed with 5 ml of 
phosphate buffered saline and centrifuged for 5 min at 200 x g. The pellet was resuspended 
in 150 µl of protein extraction reagent (M-Per, Pierce) and homogenized in a mortar. The 
homogenate was centrifuged for 5 min at 14'000 x g. The supernatant was transferred into a 
new tube, and the protein concentration was measured using the A280 method (NanoDrop; 
Witec). 
Proteins were separated by SDS-PAGE (50 µg per lane) and detected by immunoblotting. 
Anti-MCCB (Abnova) was used at a dilution of 1:1'000. Signals were detected using the ECL 
detection kit (Amersham Biosciences). 4 µg of protein was processed similarly as loading 
control and probed with a monoclonal anti-β-actin antibody (Sigma). 
 
RESULTS 
Patient MCC019 presented with severe isolated MCC deficiency shown by deficient MCC 
activity (2.2 % of median control value) together with normal PCC activity in homogenates of 
primary fibroblasts (Fig. 1). Virtually no MCCB protein was detected in fibroblasts by Western 
blotting (Fig. 1). 
Sequence analysis of MCCB RT-PCR cDNA of this proband revealed two overlapping 
transcripts (19). One contained the normal 73 bp of exon 11 with a missense mutation 
c.1054G→A (p.G352R); in the other, exon 11 was replaced by a sequence of 64 bp from 
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intron 10 (MCCB-exon10a). This cryptic exon maintains the reading frame and is flanked by 
acceptable splice consensus sites (ctttagAAA.........ATGgtaagt; average score of 86 (23)). 
Amplification and sequencing of exon 11 from genomic DNA showed that the patient was 
homozygous for c.1054G→A (Fig. 2a). However, we considered the possibility that the 
patient had a deletion of one MCCB allele being hemizygous for MCCB-p.G352R but 
rejected this possibility because the patient is the product of a consanguineous union and 
because Southern blot analysis of genomic DNA after digestion with several restriction 
enzymes showed normal amounts of MCCB and no fragments of abnormal size (not shown). 
These results indicated that the patient indeed carries the missense mutation on both alleles. 
To determine the functional consequences of the mutation, we subcloned both transcripts 
into the pTracer vector and expressed them in an immortalized MCCB-deficient reference 
cell line (Fig. 1). Transfection of the MCCB wild-type construct restored MCC activity from 
less than 1 % of the median control value to 16 %. Constructs with MCCB-G352R and 
MCCB-exon10a showed no rescue of activity, confirming the functional significance of these 
transcripts. 
Western blot of lysates of cells transfected with the MCCB-G352R construct revealed slightly 
reduced levels of MCCB protein as compared with those transfected with the wild-type 
construct. No protein was detectable after transfection with the MCCB-exon10a construct 
(Fig. 1). This finding, together with Western blot data of untransfected patient fibroblasts, 
indicates that both variants lead to protein that is less stable than the wild-type protein, and in 
the case of MCCB-exon10a, is rapidly degraded, causing absence of MCC activity. 
To visualize and assess the relative abundance of the two transcripts, we used primers in 
exon 10 (DV5020) and 12 (DV5019) to amplify either a 114 bp fragment (containing exon 11) 
or a 105 bp fragment (lacking exon 11 but containing the cryptic exon 10a) from cDNA and 
separated the products on a 12 % acrylamide gel (Fig. 2b). From patient RNA, the 114 and 
105 bp fragments were produced in the ratio of 3 to 2, respectively, whereas only the 114 bp 
fragment was produced from control RNA. Both fragments with similar relative levels were 
also obtained using RNA extracted from the lymphoblasts of the patient, indicating that this 
result is not specific for fibroblasts (not shown). 
The effect of NMD on these steady-state levels of MCCB transcripts was investigated by 
repeating RT-PCR amplification in emetine-treated cells. The most abundant MCCB 
transcript in RNA from emetine-treated patient cells was one lacking both exon 11 and 
exon 10a (Fig. 2c). This 41 bp transcript (MCCB-Δ10a, 11) results in a frame-shift followed 
by a stop codon. It was detected only after amplification of the RNA of the patient after 
emetine treatment, indicating that it is rapidly degraded by NMD under normal 
circumstances. 
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The normal exon 11 motif TATGGA was identified as a putative SR protein, SRp55-
responsive ESE, by two independent web-based ESE prediction programs, ESEfinder (24) 
and RESCUE-ESE (25), and has been shown to be capable of functioning as an ESE (26). 
This motif is mutated to TATAGA in our patient. We therefore hypothesized that the 
reduction in utilization of exon 11 associated with the c.1054G→A mutation (Fig. 2b) is due 
to disruption of this ESE. 
To confirm this hypothesis, we first investigated whether we can reproduce the skipping of 
exon 11 by expressing minigene constructs in an MCCB-deficient reference cell line 
(Fig. 3a). After transfection, we used primers complementary to OAT/exon9 (DV5114) and 
OAT/exon12 (DV5115) to amplify by RT-PCR a 292 bp fragment containing part of MCCB 
exon 9, exon 10, and exon 11 and part of exon 12. Sequencing of the products showed that 
the wild-type product had the expected size of 292 bp. In contrast, most of the product of 
G352R was 219 bp in length and lacked exon 11, a phenotype detected in the cells of the 
patient only after inhibition of NMD by emetine treatment. No fragment with the cryptic 
exon 10a in place of exon 11 was obtained (Fig. 3b). 
ESEs have been associated with exons that have weak flanking splice-sites (1, 8), and the 
donor splice-site of intron 11 is indeed weak (a score of 68 as compared with 75-98 for most 
normal exons (23)). To determine whether the presence of a stronger donor site would 
reduce dependence on the ESE, we expressed a minigene construct containing the mutated 
ESE motif in combination with an optimized donor splice-site (G352RΔss, Fig. 3a). 
Optimization of the donor splice-site indeed corrected the splicing defect and led to 
amplification of a normal sized fragment (Fig. 3b). These results confirm our hypothesis that 
MCCB c.1054G→A partially disrupts an ESE and that a functional ESE is no longer required 
when the splice donor site matches the consensus sequence. 
 
DISCUSSION 
About half of the disease-causing nucleotide substitutions have been estimated to lead to 
aberrant splicing (6, 16, 27). Typically, the abnormal splicing results from inactivation of a 
splice-site or creation of a new splice-site or interference with regulatory cis-elements, such 
as splicing enhancers or silencers. Our study of the c.1054G→A (p.G352R) mutation, 
detected in the homozygous state in the MCCB gene of patient MCC019, illustrates a 
mechanism by which a missense mutation partially disrupts an ESE causing utilization of a 
cryptic exon (exon 10a) in place of exon 11. The c.1054G→A mutation is located in the 
centre of a putative ESE motif responsive to the human SR protein SRp55 (24, 25) and 
affects a highly conserved amino acid. Previous work has shown that ESEs can compensate 
for weak 5' or 3' splice signals in exons and that strengthening of the splice consensus sites 
of an enhancer-dependent exon generally eliminates enhancer dependence (10). 
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The inclusion of exon 10a in place of exon 11 does not change the reading frame and results 
in the replacement of the normal 24 amino acid sequence encoded by exon 11 by a novel 
sequence of 21 amino acid residues. Our expression studies clearly show that MCCB-
exon10a produces no detectable MCCB, whereas some albeit slightly reduced levels of 
MCCB are produced by MCCB-G352R, suggesting that the MCCB-exon10a and to a lesser 
extent the MCCB-G352R lead to an unstable protein product. This is supported by less 
MCCB protein in patient fibroblasts as compared with control fibroblasts (Fig. 1). The 
discrepancy between the amount of MCCB protein seen in the fibroblasts transfected with 
wild-type MCCB and the level of MCC activity could probably be explained by the fact that 
transfection efficiency was quite low (9 %, data not shown), whereas at the same time, the 
few transfected fibroblasts produced massive amounts of MCCB protein due to the 
cytomegalovirus promoter present in the construct. The active MCC complex is a (αβ)6 
dodecamer, and overproduction of one of the subunits could lead to incomplete and 
therefore inactive or only partly active complexes. 
The glycine at position 352 is a highly conserved amino acid, and the possibility that this 
change is a polymorphism has previously been ruled out (19). In addition, the region of 
MCCB encoded by exon 11 is thought to be part of the 3-methylcrotonyl-CoA binding site 
that gives the enzyme its substrate specificity (18). It is highly likely that replacement of 24 
amino acids in this region and a missense mutation within this exon lead to failure of 3-
methylcrotonyl-CoA binding with deleterious functional consequences. 
The most common consequence of point mutations that affect splicing is exon skipping (16, 
28). This is especially true for point mutations disrupting ESEs (6, 15, 16, 27, 29). In our 
patient, we were only able to observe exon skipping after suppression of NMD and in our 
minigene expression system. The explanation for the predominance of a transcript resulting 
from exon skipping rather than one with inclusion of exon 10a (as in untreated fibroblast 
RNA) in our minigene system remains unclear. Preliminary attempts to correct exon-skipping 
events by repairing the sequence of damaged exonic enhancers have been proven to be 
efficient in vitro and in vivo (30-32) and hold promise for future therapeutic use. 
Cryptic exons have been shown to be activated by intronic mutations that either create or 
strengthen splice-sites, create a new branch site, or are located within a cryptic exon (5, 16, 
33-36). To our knowledge, this is the first demonstration of an exonic point mutation 
disrupting an ESE that leads to skipping of the corresponding exon and at the same time 
activates utilization of a cryptic exon from the adjacent intron. Mutations causing inclusion of 
cryptic exons may be more prevalent than the current literature suggests. Potential cryptic 
exons are frequent in introns and in some genes greatly outnumber genuine exons but are 
normally not included in the mature mRNA (4). Detection of these events in disease may be 
 46 
overlooked because introns are often excluded from mutation analysis and because it is 
often impossible or impractical to utilize cDNA for mutation analysis. 
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Figure 1: Expression of pTracer constructs with MCCB wild-type cDNA and both types of mutant cDNA of 
patient MCC019 (G352R and exon10a) in an immortalized MCCB-deficient reference fibroblast cell line. 
Untransfected control and patient MCC019 fibroblasts were also analyzed. Transfections were performed by 
electroporation, and cells were harvested 48 h later for the assay of MCC and PCC activities as well as Western 
blot analysis of MCCB using β-actin as a control. Transfection with the empty vector (vector only) was used as a 
negative control. Values are the mean of parallel determinations from a representative experiment. For further 
details, see “Experimental Procedures. ” Median control values and range (in brackets) for MCC and PCC 
activities in 30 different immortalized fibroblast cell lines are: MCC, 399 pmol/min/mg protein (220-683); and PCC, 
660 (309-840). 
 48 
(n)TATAGA(n)
MCC019, MCCB, c.1054G→Aa) Genomic PCR
normal
exon switching
bp
114
105
MCC019 wt
9 10 11 12
9 10 10a 12
b) RT-PCR
9 10 10a 11 12
MCC019 normal normalMCC019
DV5020
DV5019
c) RT-PCR after emetine treatment
normal
exon switching
exon skipping
MCC019 wtbp
114
105
41 9 10 12
9 10 11 12
9 10 10a 12
9 10 10a 11 12
exon switching
normal normal
exon switching exon skipping
DV5020
DV5019
 
Figure 2: Schematic diagram of the splicing defect found in MCC019. 
Boxes represent exons, and dark horizontal lines represent introns. a, genomic PCR of MCCB exon 11 in 
MCC019 showing the homozygous mutation. b, schematic diagram and RT-PCR products of the splicing variants. 
wt, wild-type. c, RT-PCR products after treating the cells with emetine (100 µg/ml) before harvesting the RNA. 
Emetine is used to inhibit nonsense-mediated mRNA decay (21). 
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Figure 3: In vivo splicing analysis. 
Boxes represent exons, and dark horizontal lines represent introns. The relevant portion of exon 11 and its 3'-
flanking splice-site is shown for three minigene constructs: wild-type, c.1054G→A (G352R), and c.1054G→A with 
the optimized donor splice-site (G352RΔss). 
Intronic sequences are shown in lowercase, and mutated nucleotides are shown in bold. a, schematic diagram of 
the three minigene constructs and the primers used for RT-PCR analysis. b, RT-PCR products after transfecting 
MCCB-deficient reference fibroblasts with the indicated minigene constructs and the corresponding exon 
arrangements. 
 
Supplementary table 1: Sequences of all primers used in the study. 
cactggagagagagctccgDV5115
attgaccttaacatctagtaaggDV5114
gattttcaaagcagcagaaaatgttcgtattttcaattcttcacctacttacctgtaactaatgtgtctctDV5112
gcagattcactgagttcaaagccttttatagagacacattagttacaggtaagtaggtgaagaattgaaaatacgDV5111
atagttgttacgtgttgattgcDV5110
ccaggctggaatgcaatggDV5094
gggctttggatgatcatcatgcccttcacttaactagtgaaggttgtgaggDV5050
cttgccttttttgcagattcagaaaagagagctccgttgtttccDV5049
ggagctttgatgtccgagagDV5020
acccaaatattcgagcaaatccDV5019
taggagcccccaatgatgagDV4503
cccagtttgcaggttaccagDV4498
sequence (5' - 3')primer
 
 50 
REFERENCES 
1. Black, D. L. (2003) Annu. Rev. Biochem. 72, 291-336 
2. Black, D. L. (2005) Proc. Natl. Acad. Sci. U.S.A. 102, 4927-4928 
3. Lim, L. P., and Burge, C. B. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 11193-11198 
4. Sun, H., and Chasin, L. A. (2000) Mol. Cell. Biol. 20, 6414-6425 
5. Buratti, E., Baralle, M., and Baralle, F. E. (2006) Nucleic Acids Res. 34, 3494-3510 
6. Cartegni, L., Chew, S. L., and Krainer, A. R. (2002) Nat. Rev. Genet. 3, 285-298 
7. Blencowe, B. J. (2000) Trends Biochem. Sci. 25, 106-110 
8. Graveley, B. R. (2000) RNA 6, 1197-1211 
9. Schaal, T. D., and Maniatis, T. (1999) Mol. Cell. Biol. 19, 1705-1719 
10. Nielsen, K. B., Sørensen, S., Cartegni, L., Corydon, T. J., Doktor, T. K., Schroeder, L. D., Reinert, L. S., 
 Elpeleg, O., Krainer, A. R., Gregersen, N., Kjems, J., and Andresen, B. S. (2007) Am. J. Hum. Genet. 80, 
 416-432 
11. Antonarakis, S. E., Krawczak, M., and Cooper, D. N. (2001) in Metabolic and Molecular Bases of Inherited 
 Disease, 8 Ed., (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D., eds) 8th Ed., pp. 343-377, 
 McGraw-Hill Professional, New York 
12. Dietz, H. C., Valle, D., Francomano, C. A., Kendzior, R. J., Jr., Pyeritz, R. E., and Cutting, G. R. (1993) 
 Science 259, 680-683 
13. Maquat, L. E. (2004) Nat. Rev. Mol. Cell Biol. 5, 89-99 
14. Gregersen, N., Bross, P., Andrese, B. S., Pedersen, C. B., Corydon, T. J., and Bolund, L. (2001) J. Inherit. 
 Metab. Dis. 24, 189-212 
15. Liu, H. X., Cartegni, L., Zhang, M. Q., and Krainer, A. R. (2001) Nat. Genet. 27, 55-58 
16. Wimmer, K., Roca, X., Beiglböck, H., Callens, T., Etzler, J., Rao, A. R., Krainer, A. R., Fonatsch, C., and 
 Messiaen, L. (2007) Hum. Mutat. 28, 599-612 
17. Ridout, C. K., Keighley, P., Krywawych, S., Brown, R. M., and Brown, G. K. (2008) Hum. Mutat. 29, 451 
18. Baumgartner, M. R., Almashanu, S., Suormala, T., Obie, C., Cole, R. N., Packman, S., Baumgartner, E. 
 R., and Valle, D. (2001) J. Clin. Invest. 107, 495-504 
19. Dantas, M. F., Suormala, T., Randolph, A., Coelho, D., Fowler, B., Valle, D., and Baumgartner, M. R. 
 (2005) Hum. Mutat. 26, 164 
20. Stadler, S. C., Polanetz, R., Maier, E. M., Heidenreich, S. C., Niederer, B., Mayerhofer, P. U., Lagler, F., 
 Koch, H. G., Santer, R., Fletcher, J. M., Ranieri, E., Das, A. M., Spiekerkötter, U., Schwab, K. O., Pötzsch, 
 S., Marquardt, I., Hennermann, J. B., Knerr, I., Mercimek-Mahmutoglu, S., Kohlschmidt, N., Liebl, B., 
 Fingerhut, R., Olgemöller, B., Muntau, A. C., Roscher, A. A., and Röschinger, W. (2006) Hum. Mutat. 27, 
 748-759 
21. Carter, M. S., Doskow, J., Morris, P., Li, S., Nhim, R. P., Sandstedt, S., and Wilkinson, M. F. (1995) J. Biol. 
 Chem. 270, 28995-29003 
22. Suormala, T., Wick, H., Bonjour, J. P., and Baumgartner, E. R. (1985) Clin. Chim. Acta 145, 151-162 
23. Shapiro, M. B., and Senapathy, P. (1987) Nucleic Acids Res. 15, 7155-7174 
24. Cartegni, L., Wang, J., Zhu, Z., Zhang, M. Q., and Krainer, A. R. (2003) Nucleic Acids Res. 31, 3568-3571 
25. Fairbrother, W. G., Yeo, G. W., Yeh, R., Goldstein, P., Mawson, M., Sharp, P. A., and Burge, C. B. (2004) 
 Nucleic Acids Res. 32, W187-190 
26. Fairbrother, W. G., Yeh, R. F., Sharp, P. A., and Burge, C. B. (2002) Science 297, 1007-1013 
27. Teraoka, S. N., Telatar, M., Becker-Catania, S., Liang, T., Onengüt, S., Tolun, A., Chessa, L., Sanal, O., 
 Bernatowska, E., Gatti, R. A., and Concannon, P. (1999) Am. J. Hum. Genet. 64, 1617-1631 
28. Nakai, K., and Sakamoto, H. (1994) Gene 141, 171-177 
29. Cartegni, L., and Krainer, A. R. (2002) Nat. Genet. 30, 377-384 
 51 
30. Cartegni, L., and Krainer, A. R. (2003) Nat. Struct. Biol. 10, 120-125 
31. Skordis, L. A., Dunckley, M. G., Yue, B., Eperon, I. C., and Muntoni, F. (2003) Proc. Natl. Acad. Sci. U.S.A 
 00, 4114-4119 
32. Goyenvalle, A., Babbs, A., van Ommen, G. J., Garcia, L., and Davies, K. E. (2009) Mol. Ther. 17, 1234-
 1240 
33. Highsmith, W. E., Burch, L. H., Zhou, Z., Olsen, J. C., Boat, T. E., Spock, A., Gorvoy, J. D., Quittel, L., 
 Friedman, K. J., Silverman, L. M., Boucher, R. C., and Knowles, M. R. (1994) N. Engl. J. Med. 331, 974-
 980 
34. Metherell, L. A., Akker, S. A., Munroe, P. B., Rose, S. J., Caulfield, M., Savage, M. O., Chew, S. L., and 
 Clark, A. J. (2001) Am. J. Hum. Genet. 69, 641-646 
35. Tran, V. K., Zhang, Z., Yagi, M., Nishiyama, A., Habara, Y., Takeshima, Y., and Matsuo, M. (2005) J. Hum. 
 Genet. 50, 425-433 
36. Buratti, E., Dhir, A., Lewandowska, M. A., and Baralle, F. E. (2007) Nucleic Acids Res. 35, 4369-4383 
 
 
 52 
Chapter 2 
Gene Identification for the cblD Defect of Vitamin B12 Metabolism 
 
David Coelho
‡
, Terttu Suormala
‡
, Martin Stucki
§¶
, Jordan P. Lerner-Ellis
‡║
, David S. Rosenblatt
║
, Robert F. 
Newbold
Δ
, Matthias R. Baumgartner
§
, and Brian Fowler
‡
 
 
From the 
‡
Metabolic Unit, University Children’s Hospital, 4005 Basel, Switzerland; the 
§
Division of Metabolism and 
Molecular Paediatrics, University Children’s Hospital, 8032 Zürich, Switzerland; the 
¶
Zürich Center for Integrative 
Human Physiology (ZIHP), University of Zürich, 8057 Zürich, Switzerland; the 
║
Department of Human Genetics, 
and Division of Medical Genetics, both at McGill University, H3H 1P3 Montreal, Canada; and the 
Δ
Brunel Institute 
of Cancer Genetics and Pharmacogenomics, Brunel University, UB8 3PH Uxbridge, United Kingdom. 
 
N Engl J Med. 2008 Apr 3; 358(14):1454-64. 
 
D. Coelho and T. Suormala contributed equally to this article, as did M. R. Baumgartner and B. Fowler. 
 
ABSTRACT 
BACKGROUND 
Vitamin B12 (cobalamin) is an essential cofactor in several metabolic pathways. Intracellular conversion of 
cobalamin to its two coenzymes, adenosylcobalamin in mitochondria and methylcobalamin in the cytoplasm, is 
necessary for the homeostasis of methylmalonic acid and homocysteine. Nine defects of intracellular cobalamin 
metabolism have been defined by means of somatic complementation analysis. One of these defects, the cblD 
defect, can cause isolated methylmalonic aciduria, isolated homocystinuria, or both. Affected persons present 
with multisystem clinical abnormalities, including developmental, haematologic, neurological, and metabolic 
findings. The gene responsible for the cblD defect has not been identified. 
 
METHODS 
We studied seven patients with the cblD defect, and skin fibroblasts from each were investigated in cell culture. 
Microcell-mediated chromosome transfer and refined genetic mapping were used to localize the responsible 
gene. This gene was transfected into cblD fibroblasts to test for the rescue of adenosylcobalamin and 
methylcobalamin synthesis. 
 
RESULTS 
The cblD gene was localized to human chromosome 2q23.2, and a candidate gene, designated MMADHC 
(methylmalonic aciduria, cblD type, and homocystinuria), was identified in this region. Transfection of wild-type 
MMADHC rescued the cellular phenotype, and the functional importance of mutant alleles was shown by means 
of transfection with mutant constructs. The predicted MMADHC protein has sequence homology with a bacterial 
ATP-binding cassette transporter and contains a putative cobalamin binding motif and a putative mitochondrial 
leader sequence. 
 
CONCLUSIONS 
Mutations in a gene we designated MMADHC are responsible for the cblD defect in vitamin B12 metabolism. 
Various mutations are associated with each of the three biochemical phenotypes of the disorder. 
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Vitamin B12 (cobalamin) is essential for normal development and survival in humans and 
must be obtained from animal products or supplements. Inside the cell, it is converted to two 
active cofactors, adenosylcobalamin and methylcobalamin (Fig. 1) (1). Adenosylcobalamin is 
the coenzyme for mitochondrial methylmalonyl-coenzyme A mutase, which converts L-
methylmalonyl-coenzyme A to succinyl-coenzyme A and is involved in catabolism of odd-
chain fatty acids and some amino acids. Methylcobalamin is the coenzyme for cytosolic 
methionine synthase, which converts homocysteine to methionine and is essential for normal 
one-carbon metabolism, which is in turn involved in vital cellular processes such as 
methylation and DNA synthesis (1). Disturbances of cobalamin-cofactor synthesis due to 
acquired or inherited alterations result in elevated levels of homocysteine and methylmalonic 
acid, which are associated with multisystem clinical abnormalities similar to those seen in 
patients with severe nutritional vitamin B12 deficiency, including lethargy, hypotonia, 
developmental delay, seizures, and megaloblastic anemia. 
Inborn errors of cobalamin-cofactor synthesis represent a heterogeneous and important 
group of rare disorders. Intracellular cobalamin metabolism involves multiple steps between 
the lysosomal release of cobalamin and the synthesis of adenosylcobalamin in the 
mitochondria and methylcobalamin in the cytosol. To date, nine distinct defects of this 
pathway have been defined in vitro with the use of somatic complementation analysis. The 
complementation groups thus identified have been designated cblA, cblB, cblC, cblD, cblE, 
cblF, cblG, cblH, and mut (Fig. 1) (2, 3) The responsible genes are known except for cblD, 
cblF, and cblH, although the function of some of the associated proteins is not clear. The 
cblC and cblF disorders cause combined homocystinuria and methylmalonic aciduria; cblA, 
cblB, cblH, and mut cause isolated methylmalonic aciduria; and cblE and cblG cause isolated 
homocystinuria. The cblD defect (Online Mendelian Inheritance in Man number, 277410) (2) 
is puzzling in that some patients have combined methylmalonic aciduria and homocystinuria 
(called “cblD original” by Suormala et al. (2) but herein called “cblD-combined”), some have 
only isolated homocystinuria (called “cblD variant 1” (2) or, herein, “cblD-homocystinuria”), 
and others have only methylmalonic aciduria (“cblD variant 2” (2) or, herein, “cblD-
methylmalonic aciduria”). Here, we describe our identification of the cblD gene, confirmation 
of its identity by using biochemical and molecular studies, and demonstration of functionally 
significant mutations in patients with the cblD defect. 
 
METHODS 
PATIENTS AND CELL LINES 
The study was performed between 2004 and 2007. Seven unrelated patients with the cblD 
defect were studied. Written informed consent was obtained from the parents of each patient, 
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and patients who could give assent did so. The study was approved by the local ethics 
committee. 
Cultures of skin fibroblasts were obtained for diagnostic purposes, and referring physicians 
approved the use of the samples for our investigation of the origin of the disease. We 
immortalized fibroblasts using the plasmid pRNS1 (4) and electroporation (Gene Pulser II, 
BioRad). Immortalization did not markedly affect cellular function (data not shown). 
The functional integrity of the methylmalonic acid pathway was evaluated by measuring the 
degree of incorporation of [14C]propionate into macromolecules and formation of 
adenosylcobalamin from [57Co]cyanocobalamin, as described previously (2). The integrity of 
methionine synthase in the homocysteine pathway was defined as the formation of 
methionine from [14C]formate and synthesis of methylcobalamin from [57Co]cyanocobalamin 
(2). 
Somatic complementation analysis (2) confirmed that all fibroblast cell lines from patients 
belonged to the cblD group (including one that had been used to define cblD (5)). A fibroblast 
cell line from one of the seven patients had previously been assigned to a new complement 
group (cblH) by Watkins et al. (6), but we show here that it in fact belongs to the cblD 
complement group (Fig. 1 in the Supplementary Appendix, available with the full text of this 
article at www.nejm.org). 
 
MICROCELL-MEDIATED CHROMOSOME TRANSFER 
Mouse-human monochromosomal hybrid cell lines (donor cells), each carrying a single 
human chromosome tagged with a hygromycin resistance gene (7), were used to serially 
transfect one of the immortalized cblD-homocystinuria cell lines (recipient cells) with the use 
of microcell-mediated chromosome transfer, as described previously (8) (also see Table 1 in 
the Supplementary Appendix). Cells containing each transfected human chromosome were 
selected on the basis of growth in medium containing hygromycin. Colonies were 
subcultured and assayed for methylcobalamin synthesis. Those that showed such synthesis, 
and thus the rescue of cellular function, were defined as positive colonies; those that did not 
were defined as negative colonies. 
 
GENE MAPPING 
Positive colonies were tested for contamination by mouse DNA with the use of the mouse-
specific microsatellite markers BAM5 and RSINE1 SINE/B4 (9, 10). Positive colonies that 
were free of mouse DNA contamination and negative colonies then were used in the fine 
mapping of the donor chromosome, by means of microsatellite markers, to define the 
chromosomal segment containing the putative gene corresponding to the cblD defect. The 
presence of these microsatellite markers was tested with the use of the polymerase-chain-
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reaction (PCR) assay, involving fluorescently labeled primers. Products were visualized in an 
automated sequencer (ABI Prism 3100, Applied Biosystems) and analyzed with Genotyper 
software (version 2.5, Applied Biosystems). The chromosomal region defined by the 
microsatellite markers was examined for candidate genes, and a suitable candidate was 
selected on the basis of sequence characteristics. 
 
DNA SEQUENCING AND MUTATION ANALYSIS 
Total RNA was extracted from cultured fibroblasts with the use of the RNeasy Kit (Qiagen), 
and full-length complementary DNA (cDNA) for the candidate gene was amplified by means 
of a reverse-transcriptase PCR (RT-PCR) assay involving specific primers and was 
sequenced according to the ABI BigDye method (Applied Biosystems). To confirm mutations 
identified in the RT-PCR products, the corresponding exons were amplified through the PCR 
assay from genomic DNA, with the use of flanking intronic primers, and were sequenced. 
 
EXPRESSION OF CANDIDATE GENE cDNA IN FIBROBLASTS 
Constructs containing wild-type and mutant cDNA sequences for the candidate gene were 
prepared in pTracer-CMV2 or pcDNA3.2/V5 expression vectors (Invitrogen), as described 
previously (11). Constructs were transfected into immortalized fibroblasts by means of 
electroporation. Transfection efficiency was 5 to 22 %, as determined by estimating the 
proportion of cells co-expressing the green fluorescent protein from the pTracer construct. 
Rescue of cellular function was tested by measuring methionine and methylcobalamin 
synthesis or adenosylcobalamin synthesis. 
 
STATISTICAL Analysis 
We tested the statistical significance of the data on rescue of function by using the unpaired 
t-test (two-tailed), with Welch‟s correction for unequal variances, and GraphPad Prism 
software (version 4). P values less than 0.05 were considered to indicate statistical 
significance. 
 
RESULTS 
CLINICAL DATA 
The clinical features of the seven patients are shown in Table 1. Two patients had the 
isolated homocystinuria phenotype, and two had the isolated methylmalonic aciduria 
phenotype. These four patients have been described previously (Table 1). The three other 
patients, two of whom are newly described in this study, had the combined phenotype 
(methylmalonic aciduria and homocystinuria). 
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GENE LOCALIZATION 
To identify the chromosome containing the cblD gene, we transfected immortalized cblD-
homocystinuria cells (from Patient 2) with individual human chromosomes contained in 
mouse-human single-chromosome hybrid cell lines using microcell-mediated chromosome 
transfer. We then tested the resulting cell lines for rescue of function by measuring 
methylcobalamin synthesis. Transfection with chromosome 2 yielded 48 colonies that 
showed correction of methylcobalamin synthesis (positive colonies) and 24 colonies that did 
not (negative colonies) (Table 1 in the Supplementary Appendix). The positive colonies were 
screened for mouse-specific sequences, and four were found to be free of contamination 
with mouse DNA. 
A panel of 38 microsatellite markers spanning chromosome 2 was used to perform fine 
mapping of the chromosome fragments from the 4 positive colonies and 22 of the negative 
colonies (see Table 2 in the Supplementary Appendix). This fine-mapping procedure 
identified a 10.2 Mb DNA segment between markers D2S150 and D2S2324 that was present 
in DNA from positive colonies but absent in all the negative colonies (Fig. 2 in the 
Supplementary Appendix). This mapped the cblD gene to the chromosome region 2q22.1-
2q23.3 (Fig. 2A), which contains 28 genes (according to the deCODE genetic map; for 
details, see the accession numbers and URLs in Note 1 in the Supplementary Appendix). 
The C2orf25 gene was selected as a candidate because of its homology (14) to a putative 
mitochondrial ATPase component of a bacterial ATP-binding cassette (ABC) transporter 
(YP_218380) and because cobalamin transport in bacteria is facilitated by an ABC transport 
system (15). 
 
MUTATION ANALYSIS 
The full-length cDNA for the candidate gene C2orf25 was amplified by means of RT-PCR 
and specific primers (Table 3 in the Supplementary Appendix). The C2orf25 gene was then 
sequenced from cDNA from each of the seven patients with the cblD defect, and mutations 
for each patient were identified. These mutations were further confirmed with the use of PCR 
amplification of the appropriate exons from genomic DNA, involving flanking intronic primers 
(Table 3 in the Supplementary Appendix). We identified nine mutations, with two mutant 
alleles in each patient (Table 1 and Fig. 2B). 
Five of the mutations we identified are predicted to lead to a premature stop codon, resulting 
in a truncated protein: two nonsense mutations (160C→T, 748C→T), two deletions 
(57_64del, 696+1_4del), and one duplication (419dupA). The 696+1_4del splice-site 
mutation was shown by means of RT-PCR to cause the skipping of exon 7. This mutation 
was present in the homozygous state in Patient 7 and was found in the heterozygous state in 
both parents and in an at-risk fetus in this family (data not shown). 
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One in-frame duplication (307_324dup) was identified. This mutation is predicted to add six 
amino acids to the protein product. 
Three mutations causing a single amino acid change were found (545C→A, 746A→G, and 
776T→C), each occurring in a region of the gene that is highly conserved among species 
(Fig. 3). These three missense mutations occurred in patients of European origin and did not 
occur in 100 control chromosomes from subjects with the same ethnic backgrounds, 
substantially reducing the likelihood that these are common polymorphisms. Parental DNA, 
used to rule out a deletion in the homozygous patients, was available from only one family. 
 
TISSUE EXPRESSION AND PROTEIN CHARACTERIZATION 
We searched databases of known expressed sequences of the human genome to ascertain 
the tissue expression of the C2orf25 gene. This gene appears to be expressed at high levels 
in most tissues (Note 2 in the Supplementary Appendix). To detect possible multiple 
transcripts, we amplified C2orf25 from fibroblast messenger RNA (mRNA), by using RT-PCR 
and various primers. We found only a single cDNA product, with a coding region of 891 bp, 
encoding a putative polypeptide of 296 amino acids and a predicted molecular weight of 
32.8 kDa (Fig. 3). Residues 1 through 12 constitute a possible mitochondrial leader 
sequence, which suggests targeting of the expressed protein to mitochondria (16). Residues 
81 though 86 match the vitamin B12 binding motif, Asp-Xaa-His-Xaa-Xaa-Gly, constituting a 
putative binding site for cobalamin (17). 
 
EXPRESSION OF HUMAN C2orf25 cDNA IN FIBROBLASTS 
To prove that the C2orf25 gene is responsible for the cblD phenotype, we tested the ability of 
wild-type and mutant constructs to rescue cellular function (Fig. 4). The wild-type construct 
rescued methionine synthesis and methylcobalamin synthesis, which were both restored to 
52 to 100 % of the control values in both cblD-homocystinuria and cblD-combined fibroblasts 
with the use of the pTracer vector (Fig. 4A and 4B). Adenosylcobalamin synthesis was not 
reproducibly corrected with the use of the pTracer wild-type construct. To test for rescue of 
adenosylcobalamin synthesis, we repeated the experiment with the pcDNA3.2/V5 vector 
containing the wild-type construct and showed restoration of adenosylcobalamin synthesis to 
68 % of the control value in a cblD-combined cell line (Fig. 4C). 
Constructs containing the missense alleles associated with isolated homocystinuria 
(545C→A, 746A→G, and 776T→C) did not restore methionine or methylcobalamin synthesis 
in either cblD-homocystinuria or cblD-combined cells, confirming that these mutant alleles 
cause the homocystinuria phenotype (Fig. 4A and 4B). Both constructs containing the 
mutations found in isolated methylmalonic aciduria (57_64del and 160C→T) rescued the 
synthesis of methylcobalamin (Fig. 4B). 
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Together, these findings suggest that mutations in the C2orf25 gene are responsible for the 
cblD defect. We have therefore designated the gene MMADHC, or methylmalonic aciduria, 
cblD type, and homocystinuria (to indicate either the isolated phenotype or the combined 
phenotype). 
 
DISCUSSION 
We show evidence that mutations of the gene C2orf25, which we have designated 
MMADHC, cause the cblD defect in vitamin B12 metabolism. Our evidence includes the 
identification of nonconservative mutations in MMADHC in each of seven patients with cblD 
defects and the demonstration that expression vectors containing the wild-type MMADHC 
gene rescue cblD function in fibroblast cell lines. The predicted MMADHC protein contains 
the putative cobalamin binding motif and a putative mitochondrial leader sequence. 
A complete analysis of the cblD defect requires an explanation of how mutations in the 
candidate gene lead to three distinct biochemical phenotypes. Although our data as 
described do not fully satisfy this requirement, our results suggest that the nature and 
location of the mutations are correlated with the biochemical phenotype, as illustrated in 
Figure 2B. Mutations found in the patients with cblD-methylmalonic aciduria are located 
toward the N-terminal part of the protein and consist of a nonsense mutation, a duplication, 
and a frame-shift deletion. Mutations found in the patients with cblD-homocystinuria are 
located toward the C-terminal part of the protein and consist of three missense mutations. 
Mutations found in the patients with the cblD-combined phenotype are located toward the C-
terminal part of the protein and consist of a nonsense mutation, a splice-site deletion, and a 
frame-shift duplication. 
Explaining these associations fully will require further studies. However, we offer the 
following speculations. The two patients with the cblD-methylmalonic aciduria defect carry 
mutations that are predicted to lead to truncated proteins of 19 amino acids in length 
(57_64del) or 53 amino acids in length (160C→T). We propose that the Met62 codon acts as 
a second start codon and leads to the reinitiation of translation (18), resulting in the formation 
of a shorter functional cblD protein product that lacks the putative mitochondrial leader 
sequence but allows for normal methylcobalamin synthesis. This would explain the isolated 
methylmalonic aciduria without homocystinuria in Patients 3 and 4 and is in accordance with 
the rescue of methionine and methylcobalamin synthesis in cblD-homocystinuria and cblD-
combined cell lines transfected with the mutant alleles 57_64del and 160C→T. In support of 
this “reinitiation of translation” hypothesis, a strong Kozak consensus sequence (19) occurs 
at cDNA positions 184−3 and 184+4 (A at position-3 and G at position +4) in the MMADHC 
gene. 
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Both patients with isolated homocystinuria carry missense mutations (545C→A, 746A→G, 
and 776T→C) that are sufficient to cause deficient synthesis of methylcobalamin. However, 
we speculate that these mutations allow for the formation of a modified protein with an intact 
functional domain for the synthesis of adenosylcobalamin. 
The patients with combined homocystinuria and methylmalonic aciduria carry mutations 
(419dupA, 696+1_4del, and 748C→T) that are predicted to lead to premature stop codons. 
We presume that these mutations would result either in a defective protein lacking both 
functional domains or in a low, steady-state abundance of MMADHC mRNA by the 
mechanism of nonsense-mediated mRNA decay. 
These interpretations imply that at least two functional domains are present in the cblD 
protein and that the nature and location of the mutations correlate with the biochemical 
phenotype. However, this hypothesis remains speculative until proved in more patients. An 
alternative hypothesis is that even under normal conditions, two proteins are produced. 
However, we find no evidence of two different transcripts, and a single transcript of 
MMADHC rescues both biochemical phenotypes. This gene can be added to the list of genes 
known to be associated with multiple phenotypes involving various subcellular 
compartments, such as the amnionless gene (20) and the multiple sulfatase gene (21). To 
our knowledge, MMADHC is unique in that the three distinct biochemical phenotypes involve 
both the cytosolic and mitochondrial pathways. 
The protein sequence of MMADHC is highly conserved among various mammalian species 
(Fig. 3). MMADHC is not a member of any previously identified gene family but was initially 
selected because of homology to a putative bacterial ABC transporter. 
Although the segment of 91 amino acids between residues 78 and 168 shares 28 % identity 
and 46 % similarity with a putative ATPase component of an ABC transporter from 
Salmonella enterica (YP_218380), the cblD protein lacks critical motifs of ABC transporters 
such as Walker A, Walker B, and an ABC signature (22). This makes it unlikely that the cblD 
protein is a classic ABC transporter. ABC transporters are a diverse family of proteins with 
multiple functions; MMADHC may be a new type of ABC transporter or may be involved in a 
complex that facilitates transport in a fashion similar to that of ABC transporters. 
It is not known how cobalamin enters the mitochondria in humans. Both active diffusion and 
passive diffusion have been suggested (23, 24). In some bacteria, cobalamin transport is 
facilitated by two processes. First, it is transported through the outer membrane by the BtuB 
transporter (15), which is mediated by TonB (25), a protein that couples energy from the 
proton motive force to the transport of cobalamin. Second, it is transported through the inner 
membrane by the BtuFCD ABC transport system (22). The C-terminal region of the human 
cblC protein (MMACHC) folds in a manner similar to that of TonB from Escherichia coli (26), 
and the human cblD protein MMADHC, the existence of which we have predicted, shares 
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some sequence identity with an ABC transporter from S. enterica. It is tempting to speculate 
that the MMACHC and MMADHC genes may have evolved to carry out functional roles that 
are similar to those of their bacterial counterparts, by forming structurally similar proteins. 
In conclusion, we studied seven patients with the cblD defect in vitamin B12 metabolism. We 
found that mutations in a gene we designated MMADHC are responsible for this defect, and 
we demonstrated that various mutations are associated with each of the three biochemical 
phenotypes of the disorder. 
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Figure 1: Intracellular Cobalamin Metabolism and Its Defects. 
To date, nine complementation-group defects of the cobalamin pathway have been described. Cobalamin bound 
to transcobalamin enters the cell by means of lysosome-mediated endocytosis and is released through 
proteolysis. Export from the lysosome into the cytoplasm is defective in patients with the cblF defect. The steps in 
the cytosol after lysosomal release are still unclear but are defined by the complementation groups cblC and cblD. 
In addition, the exact form of cobalamin at this stage is unclear (as indicated by “Cblx”). In the cytoplasm, 
cobalamin is reductively methylated by methionine synthase reductase (cblE) to methylcobalamin, the cofactor for 
methionine synthase (cblG). After its transport into the mitochondrion, cobalamin is converted to 
adenosylcobalamin, the cofactor for methylmalonyl-coenzyme A (CoA) mutase (mut), by cobalamin 
adenosyltransferase (cblB). The exact role of the protein associated with the cblA complementation group is 
unclear. Our studies show that the cblD protein constitutes a branch point between the cytosolic and 
mitochondrial pathways, controlled by the cblD-methylmalonic aciduria variant and the cblD-homocystinuria 
variant, respectively. We also show that the cblH complementation group is identical to the cblD-methylmalonic 
aciduria group. 
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Table 1: Mutations in Complementary DNA in Seven Patients with the cblD Defect.* 
* Fibroblast cultures from Patients 4 and 5 were obtained from the Repository for Mutant Human Cell Strains, 
Montreal Children‟s Hospital (where the patients were identified as WG1437 [cblH] and WG1220 [the original 
patient with the cblD defect], respectively). Fibroblast cultures from Patients 6 and 7 were supplied by Dr. B. 
Woldseth (Oslo, Norway) and Dr. D. Ketteridge (Adelaide, Australia), respectively. 
† Mutation numbering is based on the complementary DNA sequence (NM_015702) with +1 corresponding to the 
A of the ATG translation-initiation codon. The 696+1_4delGTGA mutation results in exon 7 being skipped. 
‡ Ethnic group was reported by the parents of the patients. 
§ Elevated excretion of methylmalonic acid was detected and treated shortly after birth, but enzymatic diagnosis 
was performed only at the age of 8 months. 
¶ The parents of this patient were from the same village. 
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Figure 2: Location, Structural Organization, and Mutations of MMADHC (Methylmalonic Aciduria, cblD 
Type, and Homocystinuria). 
Panel A shows the fragment of chromosome 2, between markers D2S150 and D2S2324, that was identified by 
means of microcell-mediated chromosome transfer and microsatellite mapping. This fragment is 10.2 Mb in 
length. The position of the markers is indicated according to the National Centre for Biotechnology Information‟s 
human reference sequence, build 36.1. MMADHC (currently named C2orf25; locus NM_015702) is located in 
chromosome 2 (genomic sequence NT_005403) and maps to chromosome region 2q23.2. The gene consists of 
eight exons. Three in-frame stop codons precede the first initiation codon (ATG) in exon 2. Exon 1 and the 5′ end 
of exon 2 are not translated. Exons 2 through 8 encode an 891 bp message, from the initiation codon to the TAG 
termination codon, predicted to encode a polypeptide of 296 amino acids with a predicted molecular mass of 
32.8 kDa. The coding regions are indicated as black vertical bars with exon numbers above and the size in base 
pairs below; intron sizes, in base pairs, are indicated between the exons. Panel B represents composite 
complementary DNA (cDNA) for MMADHC and shows the location of mutations, grouped according to the cblD 
phenotype. Exons are represented by the numbered boxes, and the numbers below the boxes indicate the 
position within the cDNA sequence of the last nucleotide of each exon. 
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Figure 3: Evolutionary Conservation of MMADHC (Methylmalonic Aciduria, cblD Type, and 
Homocystinuria). 
Amino acid sequence alignment for MMADHC and its orthologues was performed with the use of ClustalW 
software. Residues that are identical in all species listed are shown in black; residues with conservative 
substitutions are shown in grey. The portion of the sequence with genetic identity to a bacterial hypothetical 
mitochondrial ATP-binding cassette (ABC) transporter is indicated. The amino acids constituting the putative 
cobalamin binding motif are underlined (residues 81-86). Dashes represent amino acids that are absent in the 
protein of the particular species. The value along the right side of the sequences indicates the number of the last 
amino acid shown in the row. MLS denotes the putative mitochondrial leader sequence, as predicted by means of 
the Mitoprot II program. Sequences are shown for the following species (top to bottom in each group): Homo 
sapiens, Pan troglodytes, Bos taurus, Canis familiaris, Mus musculus musculus, Rattus norvegicus, Oryctolagus 
cuniculus, Mus musculus domesticus, Gallus gallus, Danio rerio, and Caenorhabditis elegans. 
 65 
 
Figure 4: Expression of Wild-Type and Mutant Alleles of Human MMADHC (Methylmalonic Aciduria, cblD 
Type, and Homocystinuria) in Immortalized cblD-Combined, cblD-Homocystinuria, and Control 
Fibroblasts. 
Cells from Patient 7 with the cblD-combined phenotype (homozygous for 696+1_4delGTGA), Patient 2 with the 
cblD-homocystinuria phenotype (cblD-HC) (compound heterozygous for missense mutations 545C→A and 
746A→G), and one control were immortalized and used for transfection experiments. Transient transfection was 
performed by means of electroporation with pTracer (pTr) vectors containing an MMADHC allele: the wild-type 
allele, one of the three missense alleles (545C→A, 746A→G, or 776T→C) associated with cblD-HC, or the frame-
shift deletion 57_64delCTCTTTAG or the nonsense mutation 160C→T associated with cblD-methylmalonic 
aciduria. Background activity was measured in cells transfected with empty pTracer vector (pTr only). Panel A 
shows the formation of methionine from [
14
C]formate, and Panels B and C show the synthesis of 
methylcobalamin, and adenosylcobalamin, respectively, from [
57
Co]cyanocobalamin. Transfection of the cblD-
combined cell line and the control cell line was also performed with the pcDNA3.2/V5 vector containing wild-type 
MMADHC. Background activity was measured in cells transfected with empty pcDNA3 vector (pcDNA3.2 only). 
The data are means, and the bars indicate the range of results of single determinations from each experiment. 
For Panels A and B, the values are from three replicate experiments, and P values are shown only for 
comparisons indicating rescue of function. For Panel C, values for the pTracer vector are from seven replicate 
experiments, and those for the pcDNA3.2 vector are from three replicate experiments. 
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Supplementary Figure : Somatic complementation analysis in cell line WG1437 (No. 4 in this paper) from 
a patient with isolated methylmalonic aciduria, previously classified as cblH. 
Complementation analysis was performed as described in reference 2 using primary fibroblasts and reference cell 
lines belonging to the known complementation groups associated with methylmalonic aciduria, i.e. cblA, cblB, 
cblC, cblF, the original cblD (cell line WG1220 from a patient with combined homocystinuria and methylmalonic 
aciduria) and cblD-MMA (cell line No. 3 from a patient with isolated methylmalonic aciduria). These cell lines were 
mixed pair-wise with the cell line WG1347 and fused with polyethyleneglycol (PEG, shaded columns +PEG) and 
4 days later incorporation of [
14
C]propionate into acid precipitable material was determined. Parallel cultures of 
mixed unfused cells were assayed as background controls (unshaded columns -PEG). Self fusions were used as 
negative controls. Columns represent mean values and the vertical lines are ranges from 4 replicate experiments, 
each with a single determination. P-values are derived from the unpaired t-test (two-tailed) with Welch‟s correction 
for unequal variances. WG1437 cells clearly complement the reference cell lines, cblA, cblB, cblC and cblF but 
not the WG1220 or cblD-MMA cells. These findings were confirmed by Dr. David Watkins (Montreal) and 
establish that WG1437 belongs to the cblD complementation group. 
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Supplementary Table 1: Cobalamin coenzyme synthesis after transfection of immortalized cblD-
homocystinuria (cblD-HC) fibroblasts with human chromosome 2 by microcell mediated chromosome 
transfer (MMCT). 
 
* Percentage of total cobalamins extracted from cells cultured for 2 days in medium containing 
[
57
Co]cyanocobalamin; OH-Cbl, hydroxocobalamin; MeCbl, methylcobalamin, AdoCbl, adenosylcobalamin; CN-
cbl, cyanocobalamin. 
#Colonies were obtained after transfer of human chromosome 2 from the mouse/human chromosome 2 hybrid 
cell line (donor cells) into immortalized fibroblasts of cblD-HC (patient No. 2) by MMCT. Microcells were produced 
from the donor cells by inducing micronucleation with colcemid treatment for 48-66 hours (0.05 mg/l; KaryoMAX, 
Gibco) and by incubation and centrifugation in the presence of cytochalasin B (10 mg/l; Sigma). They were 
purified by serial filtration through 8 μm and 5 μm polycarbonate membranes (Magna® PCTE, Osmonics). 
Attachment of microcells to donor cells was facilitated by lectin (0.1 g/l PHA-P, Sigma) and cells were fused by 
treatment with polyethyleneglycol 1450 (Sigma). Cells containing the transfected human chromosome were 
selected by growth in medium containing hygromycin (0.1 mg/l, Calbiochem), subcultured and assayed for 
cobalamin coenzyme synthesis. Values are shown for positive colonies which rescued the function and negative 
colonies which did not, and are expressed as the mean ± SD with range in brackets. Methylcobalamin synthesis 
in negative colonies is not different from that in not transfected cblD-HC cells (P=0.16), whereas in positive 
colonies it is significantly increased (P<0.001) and virtually identical to that in the control (P=0.91). 
§ For not transfected immortalized control and cblD-HC fibroblast cell lines, values are the mean ± SD with range 
in brackets from 10 and 19 replicate experiments, respectively, with single determinations. For donor cells values 
are from individual experiments with single determinations. 
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Supplementary Table 2: Markers used for mapping of chromosome 2. 
 
These markers were selected from Linkage Mapping Set v2.5 (Applied Biosystems) and from deCODE Genetics 
and Genethon genetic maps. ND: not determined. 
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Supplementary Figure 2: Fine mapping of chromosome 2 fragments. 
The human polymorphic DNA markers included in the panel are depicted in the columns labeled D2S. Other 
columns show the results obtained with the various colonies and each line corresponds to a different marker. 
Results obtained with positive colonies are represented on the left side of the table and those obtained with 
negative colonies are on the right. Shaded areas indicate the presence of a marker in DNA from the particular 
colony. The only marker present in all positive colonies and absent in all negative colonies is D2S151 located 
between D2S150 and D2S2324. Complete mapping was performed for the 11 negative colonies shown here. Fine 
mapping was performed with selected markers in another 11 negative colonies. The marker, D2S151 was absent 
in all negative colonies. 
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Supplementary Note 1: accession codes and URLs 
C2orf25: Unigene Hs.5324, NM_015702, NP_056517. 
Putative ATPase component of ABC transporter with ATPase domain: YP_218380.1. 
Orthologs of MMADHC used for alignment in Figure 2: 
Pan troglodytes, NP_001004280.1; Bos taurus, NP_001029713; Canis familiaris, XP_533352; Mus musculus, 
NP_598600.1; Rattus norvegicus, NP_001004280.1; Oryctolagus cuniculus, Ensembl Translation ID 
ENSOCUP00000007023 ; Monodelphis domestica, Ensembl Translation ID ENSMODP00000004357 ; Gallus 
gallus, CAG31701.1; Danio rerio, NP_991157; Caenorhabditis elegans, NP_499801. 
 
URLs 
Mitoprot II software: http://ihg.gsf.de/ihg/mitoprot.html 
Predotar software: http://urgi.versailles.inra.fr/predotar/french.html 
TargetP software: http://www.cbs.dtu.dk/services/TargetP 
Mitopred software: http://bioinformatics.albany.edu/~mitopred 
MultiLOC software: http://www-bs.informatik.uni-tuebingen.de/Services/MultiLoc 
PSORT II software: http://psort.nibb.ac.jp/form2.html 
iPSORT software: http://hc.ims.u-tokyo.ac.jp/iPSORT 
HSLPred software: http://www.imtech.res.in/raghava/hslpred 
ESLPred software: http://www.imtech.res.in/raghava/eslpred 
Primer 3.0 software: http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi 
 
DeCODEgenetic map: http://www.decode.com 
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Supplementary Table 3: Primers used to amplify MMADHC exons and cDNA. 
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Supplementary Note 2: tissue expression. 
Based on expressed sequence tags (ESTs) examined in the dbEST database, UniGene (www.ncbi.nlm.nih.gov) 
and a comprehensive annotation of C2orf25 in AceView (The AceView genes: www.ncbi.nlm.nih.gov/IEB/-
Research/Acembly: Danielle and Jean Thierry-Mieg, Michel Potdevin, Mark Sienkiewicz. AceView: Identification 
and functional annotation of cDNA-supported genes in higher organisms), the MMADHC gene appears to be 
expressed at high levels in most tissues. 1'437 ESTs from multiple tissues were listed in the UniGene cluster 
Hs.5324 including brain, skin, bone marrow, testis, bladder, kidney, vascular tissue, esophagus, muscle, salivary 
gland, prostate, placenta, liver, lung, mammary gland, embryonic tissue, lymph, cochlea, ascites, uterus, blood, 
rectum, small intestine, whole brain, pharynx, bone, connective tissue, stomach, thymus, uncharacterized tissue, 
tonsil, heart, cervix, pancreas, colon, lymph node, umbilical cord, ovary, parathyroid, eye, pituitary gland, adipose 
tissue, spleen, mouth, trachea, adrenal gland and nerve. 
According to AceView, 8 different splice products are produced encoding 8 different putative protein isoforms, 
three of which (transcript a, b and c) are complete cDNAs matching the genome and each supported by more 
than 100 EST clones. Transcript c is an mRNA of 1415 bp with an ORF of 891 bp encoding a putative polypeptide 
of 296 amino acids identical to 15 different clones (AF131802, CR626278, CR624911, CR612420, CR611592, 
CR596944, CR595331, CR594994, CR592888, BC000932, AF060224, BC010894, BC023995, BC022859, 
AF161510). In contrast, according to AceView, the putative transcripts a and b encode slightly larger proteins of 
380 and 330 amino acids, which are each supported only by a single clone (CR596944 and CR595331, 
respectively). Both include transcript c but in addition have 84 amino acids at the N-terminus (transcript a) or 34 
amino acids in the C-terminal part of the polypeptide (transcript b). The 3 transcripts appear to differ because an 
internal intron (intron 1) is not always spliced out (transcript a) or because an additional exon (after exon 6) is 
present (transcript b). 
To experimentally verify this in silico data we performed RT-PCR amplification of fibroblast mRNA using primers 
in the 5‟UTR and 3‟UTR of the different putative transcripts. Only transcript c could be amplified. Further, we 
performed RT-PCR experiments using primers flanking the additional exon of the putative transcript b, but were 
not able to amplify this transcript. From these experiments we conclude that transcript c was the only authentic 
transcript in fibroblasts, a tissue in which this gene is expressed with measurable activity. 
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ABSTRACT 
BACKGROUND 
The cblD defect of intracellular vitamin B12 metabolism leads to three distinct biochemical and clinical phenotypes. 
Depending on the location of the mutation in the MMADHC gene, the cell is still capable of forming 
methylcobalamin in the cytosol or adenosylcobalamin in mitochondria, the two cofactors required for methionine 
synthase and methylmalonyl-CoA mutase, respectively. Defects in MMADHC can thus lead to either isolated 
methylmalonic aciduria (cblD-MMA) or homocystinuria (cblD-HC), or, if both pathways are affected, to combined 
methlymalonic aciduria and homocystinuria (cblD-MMA/HC). This study focused on the elucidation of how 
mutations in MMADHC lead to three phenotypes. We provide evidence that reinitiation of translation at 
downstream AUGs explains the phenotypes found in cblD patients. 
 
METHODS 
We studied the effect of various constructs on rescue of adenosyl- and methylcobalamin formation. Expression 
vectors containing the wildtype MMADHC were modified by PCR to include an enhanced mitochondrial leader 
sequence or mutations changing possible downstream sites of reinitiation or mutations introducing stop codons. 
The constructs were transfected into cell lines derived from cblD patient's fibroblasts. In vitro 
transcription/translation was used to investigate reinitiation of translation. 
 
RESULTS 
In cblD-MMA/HC cells, improving mitochondrial targeting of MMADHC clearly increased the formation of 
adenosylcobalamin with a concomitant decrease in methylcobalamin formation. In cblD-MMA cells, this effect was 
dependent on the mutation found in the corresponding cell line and showed a negative correlation with 
endogenous MMADHC mRNA levels. Transcriptional initiation at Met116 is sufficient for rescue of 
methylcobalamin formation and the sequence between Met62 and Met116 seems important for rescue of 
adenosylcobalamin formation. 
 
CONCLUSIONS 
These new findings support our hypothesis that the nature and location of MMADHC mutations correlate with the 
phenotype and that a delicate balance exists between cytosolic MeCbl and mitochondrial AdoCbl synthesis, 
supporting the role of cblD protein as a branching point in intracellular cobalamin trafficking. Furthermore our data 
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indicate that the sequence after Met116 is sufficient for MeCbl synthesis whereas the sequence between Met62 
and Met116 is required for AdoCbl synthesis. 
 
In mammals vitamin B12 (cobalamin) is essential for normal development and survival and 
must be provided in the diet from animal products or from supplements. It is converted 
intracellularly to two active coenzyme forms, adenosylcobalamin (AdoCbl) and 
methylcobalamin (MeCbl). AdoCbl is the coenzyme for mitochondrial methylmalonyl-CoA 
mutase (MIM 609058) which converts L-methylmalonyl-CoA to succinyl-CoA and is involved 
in catabolism of odd-chain fatty acids and some amino acids. MeCbl is the coenzyme for 
cytosolic methionine synthase (MIM 156570) which converts homocysteine to methionine 
and is essential for normal one-carbon metabolism (1). 
Increases of plasma homocysteine are associated with homocystinuria (HC) and with a 
number of disease states such as vascular disease, birth defects, cancer and neuro-
psychiatric disorders linking disorders of cobalamin metabolism to common diseases (2-6). 
Accumulation of L-methylmalonyl-CoA leads to methylmalonic aciduria (MMA) that has been 
associated with various disease states such as acute metabolic decompensation with 
encephalopathy that can lead to death, chronic failure to thrive, developmental retardation 
and renal failure (7,8). 
 
To date, nine different complementation classes causing defects of intracellular cobalamin 
metabolism have been described (complementation groups cblA, cblB, cblC, cblD-MMA, 
cblD-HC, cblD-MMA/HC, cblE, cblF and cblG) (9-11). The cblC, cblD-MMA/HC and cblF 
disorders cause combined homocystinuria and methylmalonic aciduria (MMA/HC), the cblA, 
cblB and cblD-MMA isolated MMA and the cblD-HC, cblE, cblG isolated HC with variable 
clinical presentation. 
The cblD defect is unique in that it is associated with three distinct biochemical phenotypes. 
Three individuals have been identified with deficient synthesis of both cobalamin coenzymes 
causing combined methylmalonic aciduria and homocystinuria (cblD-MMA/HC), two with 
deficiency of MeCbl synthesis and isolated homocystinuria (cblD-HC) and two with deficient 
synthesis of AdoCbl and isolated methylmalonic aciduria (cblD-MMA) (11). Clinical 
presentation is variable with onset ranging from infancy to adolescence. CblD-MMA/HC 
patients presented with development delay, seizures, hypotonia, lethargy and megaloblastic 
anemia, CblD-HC patients with development delay, ataxia and megaloblastic anemia and 
cblD-MMA patients had respiratory distress, cranial haemorrhage, seizures and an abnormal 
EEG (9,11). The gene responsible for the cblD phenotype was designated MMADHC 
(methylmalonic aciduria, cblD type, and homocystinuria). 
While individuals suffering from cblD-MMA have at least one allele carrying a nonsense 
mutation in the N-terminal part of the protein, patients with cblD-HC carry missense 
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mutations located in the C-terminal part of the protein. The combined phenotype is 
associated with deleterious nonsense and missense mutations in the middle of the protein 
(9). 
To exert its two functions, MMADHC most likely localizes to both, mitochondria and cytosol. 
A common mechanism to achieve dual localization besides alternative splicing is the use of 
organellar targeting sequences. It has been shown that the mitochondrial leader sequence 
(MLS) can shift the balance between mitochondrial and cytosolic dual localization (12). To 
direct proteins, both natural and synthetic, to mitochondria, the MLS of aldehyde 
dehydrogenase 2 (ALDH2), known for its efficient mitochondrial import, has been widely 
used in experimental settings (13). 
Another possibility of dual localization is that ribosomes miss the first AUG (start) codon and 
start translation at another in-frame downstream initiation codon producing a shorter protein 
with the same C-terminus (14-16). This additional site of translational initiation can be 
another in-frame AUG (17,18) or even a codon other than AUG as it has been described in 
plants, yeast and mammalian cells (19-26). 
 
In this study we show that reinitiation of translation at a downstream AUG can explain the 
phenotype found in cblD-MMA patients. We provide evidence that the sequence between 
Met62 and Met116 is important for the synthesis of mitochondrial AdoCbl and the sequence 
after Met116 is sufficient for cytosolic MeCbl synthesis. Further, we report five new cblD 
patients and show functional expression of four new mutations (c.60insAT, c.133dupG, 
c.683C>G and c.737A>G) which further confirm our proposed genotype-phenotype 
correlation.  
 
METHODS 
CELL CULTURE 
Fibroblasts were obtained for diagnostic purposes from the patients with inform consent. The 
referring clinicians approved the use of the cells for our investigation of the origin of the 
disease. Fibroblasts were routinely grown in Earl‟s minimal essential medium (Amimed, 
Basel, Switzerland) supplemented with 10 % fetal bovine serum (Amimed) as described 
earlier (27). Fibroblasts were immortalized using the plasmid pRNS1 (28) and 
electroporation. 
 
MOLECULAR GENETIC STUDIES 
Genomic DNA and total RNA were extracted from cultured fibroblasts using the QIAamp 
DNA Mini Kit and RNeasy Kit (Qiagen, Hombrechtikon, Switzerland), respectively. For 
mutation analysis genomic DNA and cDNA synthesized from total RNA by reverse 
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transcription (RT-PCR) were PCR amplified using specific primers as described earlier (9). 
Sequencing was performed by the ABI BigDye method (Applied Biosystems, Rotkreuz, 
Switzerland). 
 
PREPARATION OF CONSTRUCTS FOR TRANSFECTION 
Constructs containing the MMADHC wildtype and mutant cDNA were prepared in pTracer-
CMV2 expression vectors as described earlier (29). Shortly, cDNA was produced from total 
RNA by reverse transcription using the Titan One Tube RT-PCR Kit (Roche, Basel, 
Switzerland), cloned into pCR-Blunt-II-TOPO (Invitrogen, Basel, Switzerland), subcloned into 
pTracer-CMV2 (Invitrogen) at the EcoRI site, propagated in E.coli DH5α competent cells 
(Invitrogen). Plasmids for transfections were isolated using the QIAfilter Plasmid Maxi Kit 
(Qiagen). 
By using oligonucleotides, the mitochondrial leader sequence of aldehyde dehydrogenase 2 
(MLRAAARFGPRLGRRLLSAAATQA (30) was added to wildtype MMADHC cDNA at different 
positions. The same procedure was used to N-terminally truncate MMADHC. Mutations were 
inserted into the wildtype cDNA by site-directed mutagenesis using oligonucleotides 
containing the mutant sequence. All PCR reactions were carried out using Hot Gyro 
Polymerase (Solis Biodyne, Tartu, Estonia). Primers used in the study are listed in 
Supplementary table 1. PCR products were cloned into pTracer-CMV2 as described above. 
 
TRANSFECTION STUDIES 
Constructs containing wildtype and different mutant cDNA sequences in pTracer-CMV2 
vector were transfected in immortalized patient and control fibroblasts by electroporation as 
described earlier (9). Rescue of cellular function was tested by measuring the synthesis of 
methylcobalamin and/or adenosylcobalamin from [57Co]cyanocobalamin, as described 
previously (11). 
 
RNA EXTRACTION AND REAL-TIME PCR 
cDNA was synthesized from total RNA using the TaqMan Reverse Transcription Reagent 
(Applied Biosystems). Analysis of the abundance of the MMADHC mRNA was performed 
using the TaqMan Universal PCR Master Mix (Applied Biosystems) according to the 
manufacturers recommendations, except that the total reaction volume was decreased to 
10 µl. The TaqMan probes (Applied Biosystems) used were Hs00739517_g1 (MMADHC) 
with Hs00608519_m1 (MRPL19) and Hs99999905_m1 (GAPDH) serving as controls. 
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IN VITRO TRANSLATION 
Wildtype and mutant MMADHC proteins were synthesized in vitro using the TNT T7 Quick 
for PCR DNA kit (Promega, Dübendorf, Switzerland) according to manufacturer‟s 
instructions. First, RT-PCR was performed as described above. The specific primers used to 
produce MMADHC cDNA were modified by inserting the consensus sequence of the T7 
promoter to 5‟ end of the 5‟ primer and a polyA tail to the 3‟ end of the 3‟ primer. The 
obtained PCR products were used as a template for the TNT reaction. Each reaction 
contained 20 µl of TNT master mix, 0.5 µl of 1 µM methionine, 2.5 µl of template, 1 µl of 
biotin-lysyl-tRNA and 25 µl of nuclease-free water. Samples were incubated for 75 min at 
30°C. Proteins were separated by SDS-PAGE on a 12 % gel, transferred to polyvinylidene 
difluoride membranes, and blocked at room temperature for 1 hour with TBS containing 
0.1 % Tween 20 (TBS-T) supplemented with 5 % skim milk. Membranes were then incubated 
with streptavidin-alkaline phosphatase (Promega) for 1 hour. After several washes with TBS-
T and distilled water, membranes were incubated with the Western blue substrate (Promega) 
until the bands became visible. As protein marker we used Kaleidoscope Precision Plus 
(BioRad, Reinach, Switzerland). 
 
RESULTS 
MUTATIONS DETECTED IN cblD PATIENTS 
The previous reports of ten patients (9,31) can now be extended by five new patients (Table 
1). In these five patients (D010, D012 – D015) we detected five different mutations, 1 of 
which is novel, c.133dupG, detected in the homozygous state in patient D012. Table 1 
summarizes the patients and mutations. 
 
EVALUATION OF FUNCTIONAL CONSEQUENCES OF MUTANT ALLELES 
Expression studies in a cblD-MMA/HC cell line confirmed the functional consequences of the 
novel c.133dupG mutation as well as the c.60insAT, c.683C>G and the c.737A>G mutations 
described in (31) (see Supplementary Figure 1). 
We show that cDNAs containing a mutation associated with cblD-HC phenotype (c.746A>G; 
c.776T>C) were unable to rescue MeCbl synthesis. MeCbl synthesis could be rescued by 
constructs containing the c.60insAT or the c.133dupG mutation associated with cblD-MMA 
phenotype, whereas a construct carrying a nonsense mutation (c.683C>G), associated with 
cblD-MMA/HC phenotype and the missense mutation c.737A>G associated with cblD-HC 
phenotype were unable to correct MeCbl synthesis. 
Furthermore, we show that 3 of the 4 missense mutation associated with cblD-HC phenotype 
(c.737A>G, c.746A>G, c.776T>C) rescue AdoCbl synthesis when transfected into cblD-
MMA/HC fibroblasts. The fourth missense mutation (c.545C>A) detected in the heterozygous 
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state together with c.746A>G in one cblD-HC patient (D002) as well as the nonsense 
mutation (c.683C>G) associated with the cblD-MMA/HC phenotype did not correct AdoCbl 
nor MeCbl synthesis indicating that they both represent null mutations. 
 
RESCUE OF AdoCbl SYNTHESIS IN cblD-MMA CELLS 
In earlier studies we showed that AdoCbl synthesis was poorly corrected by transfection with 
the wildtype cDNA, except when using a vector in which a V5-polypeptide was attached to 
the C-terminus of the wildtype protein (9). 
We hypothesized that the low efficiency of rescue of AdoCbl synthesis by the wildtype 
construct is caused by inefficient mitochondrial targeting. Analysis of the cblD-amino acid 
sequence by the Mitoprot software (32) predicted a cleavable, N-terminal mitochondrial 
leader sequence (MLS) of 11 amino acids. 
To investigate the efficiency of the endogenous MLS we prepared a wildtype construct 
(cblD_MLS_ALDH2) in which this putative MLS (Met1-Val12) was replaced by the potent 
MLS of aldehyde dehydrogenase 2 (ALDH2, NP_000681) which has previously been shown 
to effectively target natural and synthetic polypeptides to the mitochondria (13). Transfection 
of this construct into a cblD-MMA/HC (D007) cell line resulted in a dramatic increase of 
AdoCbl synthesis to high normal or elevated levels (Figure 1), and in a simultaneous 
decrease of the level of rescue of MeCbl synthesis. 
 
Transfection of cblD-MMA fibroblasts with the cblD wildtype construct resulted in hardly any 
increase of AdoCbl synthesis, and, in contrast to findings in cblD-MMA/HC cells, transfection 
with cblD_MLS_ALDH2 failed to normalize AdoCbl synthesis (Figure 2). After Transfection of 
wt cblD into both cell lines homozygous for c.57_64del (D003 and D010) and into the cell line 
homozygous for c.133dupG (D012) AdoCbl synthesis increased from 1 % of total cobalamins 
to only 2.0 – 2.7 % (P=0.025 in D003, P=0.146 in D010 and P=0.073 in D012) whereas 
transfection of wt cblD into cell lines compound heterozygous for a mutation leading to N-
terminal stop and a deleterious mutation in the middle of the gene led to a more prominent 
increase from 1 % to 3.8 % in D008 (P=0.020) and to 10.5 % in D004 (P=0.004) (Figure 2). 
Transfection had no substantial effect on the normal level of MeCbl synthesis in any of the 
cblD-MMA cell lines (not shown). The exception was cell line D004 in which MeCbl was 
reduced from 57.9 % to 46.6 % (P=0.044). 
Attempts to increase the level of rescue of AdoCbl synthesis with the cblD wildtype cDNA in 
two cblD-MMA cell lines homozygous for the 57_64del change (D003 and D010) by using 
another type of vector (pcDNA3) for transient transfection or by using stable transfection in a 
retroviral system (pBABE) were not successful. When using the retroviral system, again only 
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a small but statistically significant (P=0.0004) increase of AdoCbl from 1.3 % to 3.4 % was 
seen (Supplementary Figure 2). 
 
MMADHC mRNA EXPRESSION 
Real-time PCR showed considerable differences in the levels of MMADHC mRNA in the cblD 
cell lines (Figure 3). Clearly reduced levels were obtained in D006 a patient with the cblD-
MMA/HC phenotype and in D004 with the cblD-MMA phenotype. In all other cell lines the 
expression varied from 0.6 to 1.4 when compared to that of three control cell lines 
(normalized to mRNA levels of GAPDH). 
There seems to be a negative correlation between the levels of expression of MMADHC 
mRNA and the level of rescue of AdoCbl synthesis in the different cblD-MMA cell lines 
described above. Similar results were obtained when the mRNA levels were normalized to 
the mRNA of the mitochondrial protein MRPL19 (not shown). 
 
EFFECT OF MUTATIONS ASSOCIATED WITH cblD-MMA ON THE LEVEL OF AdoCbl 
SYNTHESIS 
The negative correlation observed between the level of the rescue of AdoCbl synthesis and 
the level of mRNA among the cblD-MMA cell lines indicates that the endogenous mutant 
protein in these cells may influence the ability of the wildtype protein to produce AdoCbl. We 
therefore studied the effect of the four cblD-MMA associated mutations on rescue of AdoCbl 
synthesis by transfecting a cblD-MMA/HC cell line (D007) simultaneously with 
cblD_MLS_ALDH2 and constructs carrying cblD-MMA associated mutations (Figure 4). 
Cotransfection with empty-vector, the wildtype and a construct containing the nonsense 
mutation c.683C>G/p.S228X associated with the cblD-MMA/HC phenotype were used as 
controls. 
When compared to co-transfection of cblD_MLS_ALDH2 with empty vector, co-transfection 
with the c.683C>G construct showed no effect (P=0.267) whereas co-transfection with the 
wildtype resulted in a significant decrease of AdoCbl synthesis from 18 % of total cobalamins 
to 12 % (P=0.004). Cotransfection with constructs containing three of the cblD-MMA 
associated mutations c.57-64del, c.60insAT, and the c.133dupG, reduced the rescue of 
AdoCbl synthesis to significantly lower levels as compared with the wildtype construct, i.e. to 
5.1 % (P=0.0003), 5.9 % (P=0.001) and 8.2 % (P=0.008), respectively. The reduction 
achieved with the c.160C>T construct (to 10.5 %) did not differ from that obtained with the 
wildtype construct (P=0.366). When transfecting cblD-HC fibroblasts with these four cblD-
MMA associated mutations, a significant drop of MeCbl synthesis with a parallel increase in 
AdoCbl synthesis was seen with the c.57-64del construct (Supplementary Figure 3).A similar 
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effect was seen for the c.60insAT and the c.133dupG but not for c.160C>T construct 
(Supplementary Figure 3). 
These findings are in accordance with the variable levels of mRNA and rescue of AdoCbl 
synthesis in the different cblD-MMA cell lines and indicate that these mutant proteins indeed 
interfere with the wildtype protein by inhibiting AdoCbl synthesis to various degrees. 
 
REINITIATION OF TRANSLATION 
All five patients with the cblD-MMA phenotype have at least one allele carrying a mutation 
that leads to premature termination of translation before the second methionine located at 
position 62 (Table 1). The two compound heterozygous patients carry in addition a deletion 
that leads to frameshift and premature termination at amino acid residue 162 (D008), and an 
in-frame duplication of the amino acids 103 to 108 (D004), thus mutations that most probably 
result in an inactive and/or unstable protein. All cblD-MMA patients must at least express a 
partially active MMADHC protein since MeCbl synthesis is completely normal in these 
patients. We therefore speculated that there is reinitiation of translation at a downstream 
AUG codon, e.g. at Met62 (2nd methionine-residue) and/or at Met116 (3rd methionine-
residue), which are both are located within a reasonable Kozak consensus sequence (33). 
To investigate this we made constructs with selected changes in the cblD wildtype cDNA, 
transfected them into a cblD-MMA/HC cell line (D007) and investigated the rescue of 
cobalamin coenzyme synthesis. As shown in Figure 5a transfection with cDNA truncated N-
terminally to Met62 or Met116, with cDNA with a stop-codon introduced between Met62 and 
Met116 (p.S89X), results in the same level of rescue of MeCbl synthesis as transfection with 
the unchanged wildtype cDNA, whereas no rescue was obtained with cDNA in with codon 
Gln118 was mutated to a termination codon (p.Q118X). These finding confirm that translation 
can be initiated not only at the codon for Met1 but also at the codons for Met62 and Met116 
but that no initiation of translation occurs downstream of Met116. 
We also tested whether reinitiation of translation also occurs in the wildtype: It has been 
shown that no translational initiation occurs at glutamine residues (24), we therefore tested a 
cDNA in which both Met62 and Met116 are mutated to glutamine (CAG). Our results show 
that the full-length protein (containing the endogenous MLS) with no possibility of reinitiation 
of translation at Met62 and Met116 produced normal levels of MeCbl, suggesting that 
reinitiation of translation plays a minor role in the wildtype and that the full length protein is 
dually localized.  
As expected transfection with the constructs resulting in deletion of the N-terminal 61 or 115 
amino acids were not able to rescue AdoCbl synthesis as they lack a MLS (Figure 5b). 
However, addition of the MLS of ALDH2 N-terminally to Met62 resulted in rescue of AdoCbl 
synthesis whereas no rescue was observed when the MLS was attached in front of Met116. 
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This indicates that the sequence between Met62 and Met116 is essential for AdoCbl 
synthesis. 
 
CONFIRMATION OF TRANSLATIONAL REINITIATION USING IN VITRO PROTEIN 
SYNTHESIS 
Western blot analysis of in vitro synthesized proteins (Figure 6) showed that 2 bands are 
produced when the wildtype cDNA is used as template, one corresponding to the full-length 
MMADHC protein (32.9 kDa), and the other corresponding to a protein with initiation of 
translation at Met62 (26.5 kDa). 
A shorter protein band with the expected size of 26.5 kDa was obtained from cDNA of a 
patient with the cblD-MMA phenotype (D003), corresponding to reinitiation of translation at 
Met62. Shorter protein bands of the expected sizes were also found from cDNA of three 
patients with the cblD-MMA/HC phenotype, i.e. D007 with predicted protein of 29.8 kDa due 
to deletion of exon 7 (F204_A232), D005 with predicted protein of 27.8 kDa due to premature 
termination of translation at R250, and D009 with predicted protein of 25.3 kDa due to 
premature termination at S228. No detectable protein was obtained when cDNA from patient 
D006 with a predicted protein of 15.3 kDa due to premature termination of translation at 
Y140 was used as template. 
None of the cblD patients carries mutations between Met62 and Met116, and no protein 
band corresponding to transcriptional initiation at Met116 (20.5 kDa) was obtained after in 
vitro protein synthesis from cDNA of the patients or controls. However, this short protein 
could be produced in vitro using the construct with cDNA truncated N-terminally till the codon 
for Met116 as template (not shown). These results indicate that two proteins are produced 
from the unchanged wildtype cDNA corresponding to translational initiation at Met1 and Met 
62. 
 
DISCUSSION 
Dual localization of proteins has been shown to be caused by various mechanisms including 
alternative splicing, initiation codon scan-through, multiple in-frame start codons, incomplete 
secretion, reverse translocation, spontaneous folding and others (16,18,34-38).  
Furthermore proteins that are localized in mitochondria and the cytosol have been shown to 
have weak mitochondrial leader sequences (MLS) (39). Thus the strength of the 
mitochondrial leader sequence can shift the balance between mitochondrial and cytosolic 
localization (12). 
We show evidence that the intracellular balance of MMADHC localization can be changed by 
exchanging the putative endogenous MLS of MMADHC with that of ALDH2 
(cblD_MLS_ALDH2). By doing so, the synthesis of mitochondrial AdoCbl increases and 
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concomitantly cytosolic MeCbl synthesis decreases. Or results suggest that under 
physiological conditions, there is a delicate balance of intracellular localization of MMADHC. 
So far, all patients with the cblD-MMA phenotype carried at least one allele with a nonsense 
mutation prior to the second methionine located at position 62 of MMADHC. Transcriptional 
initiation at this position could therefore also explain the dual localization of the MMADHC 
protein. A full-length protein starting at Met1 could be responsible for AdoCbl synthesis and a 
shorter protein starting at Met62 for MeCbl synthesis. Another methionine located at position 
116 could also act as point of translational reinitiation. To exclude the possibility that MeCbl 
synthesis is the result of a shorter protein produced, we mutated the second and third ATG to 
a CAG as it has been shown that this triplet does not serve as an initiation codon (24). When 
transfecting cblD-MMA/HC cells with this construct we saw no difference in MeCbl synthesis 
when compared to transfection with the wildtype constuct, suggesting dual localization is 
really caused by the weak endogenous MLS or by other factors involved in mitochondrial 
translocation, rather than by transcriptional initiation at multiple AUGs. 
To our surprise AdoCbl formation could not be rescued in cblD-MMA patients to the same 
extent as in cblD-MMA/HC patients, even when using the cblD_MLS_ALDH2 construct. As 
we observed a negative correlation between the level of endogenous MMADHC mRNA and 
the level of AdoCbl rescue, our results suggest that in these patients the endogenous mRNA 
and/or MMADHC protein interacts or competes with mRNA or the protein derived from the 
transfected construct. If MMADHC is part of a complex necessary for the formation of 
AdoCbl, a shorter MMADHC protein produced in cblD-MMA cells due to reinitiation of 
translation at Met62 could block formation of functional complexes thereby reducing AdoCbl 
synthesis. Another possibility is that the short polypeptides that are produced in cblD-MMA 
patients (from Met1 to the stop codon resulting from the mutation) interacts with the 
transfected full length protein or with binding partners located in the cytosol or at the 
mitochondrial membrane. 
Double transfection of cblD-MMA/HC cells with the cblD_MLS_ALDH2 and a cblD-MMA 
construct show the same inhibition. Again co-transfection with the c.160C>T construct had 
the highest AdoCbl forming activity reflecting the negative correlation between the mRNA 
stability of this construct with the ability to form AdoCbl. 
 
Using truncated proteins starting at Met62 and Met116 as well as site-directed mutagenesis 
introducing nonsense mutations at positions 89 (p.S89X) and 118 (p.Q118X), we provide 
evidence that translational initiation at position 116 is sufficient for MeCbl synthesis. 
However, up to now, no patient has been reported having an allele with a nonsense mutation 
between Met62 and Met116. Therefore it remains to be determined if our finding holds true 
under physiological conditions in a patient carrying such a mutation. 
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Furthermore by adding the MLS of ALDH2 to the two truncated constructs, our results 
suggest that the sequence between Met62 and Met116 is important for AdoCbl formation. 
Physiologically this finding has no implications as a construct starting at Met62 does not have 
a MLS and is not targeted to mitochondria. 
In vitro transcription/translation, supports our hypothesis of reinitiation of translation at Met62, 
from a wildtype construct two proteins are produced, one starting at Met1, the other starting 
at Met62. It remains to be determined if this holds also true in control cells when looking at 
endogenous protein levels. To answer this question, western-blotting will be necessary using 
a specific anti-MMADHC antibody. 
Similarly one would expect a single 26.5 kDa protein being produced from cDNA truncated 
N-terminally to Met62. Also in a construct in which the codons for Met62 and Met116 are 
mutated to glutamine one would only expect a single band corresponding to the full length 
protein. 
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Table 1: Clinical phenotype, mutations and location of the mutation(s) detected in MMADHC patients. 
WG1220 in MO, Pat 5 in DC8p.R250Xc.748C>Tp.R250Xc.748C>TMMA/HCD005
Pat 7 in DCintron 7p.F204_A232delc.696+1_4delGTGAp.F204_A232delc.696+1_4delGTGAMMA/HCD007
WG3583 in MO7p.S228Xc.683C>Gp.S228Xc.683C>GMMA/HCD009
Pat 6 in DC5p.Y140Xc.419dupAp.Y140Xc.419dupAMMA/HCD006
Pat. 1 in DC8p.L259Pc.776T>Cp.L259Pc.776T>CHCD001
this study8p.Y249Wc.746A>Gp.Y249Wc.746A>GHCD014
this study8p.Y249Wc.746A>Gp.Y249Wc.746A>GHCD013
this study8p.D246Gc.737A>Gp.D246Gc.737A>GHCD015
WG3745 in MO8p.D246Gc.737A>Gp.D246Gc.737A>GHCD011
Pat 2 in DC6, 8p.Y249Wc.746A>Gp.T182Nc.545C>AHCD002
WG1437 in MO; Pat 4 in DC4p.L103_S108dupc.307_324dupp.R54Xc.160C>TMMAD004
this study3p.A45fsX59c.133dupGp.A45fsX59c.133dupGMMAD012
WG3280 in MO3, 5p.T152fsX162c.455dupCp.L20fsX21c.60insATMMAD008
this study3p.C19fsX20c.57_64delCTCTTTAGp.C19fsX20c.57_64delCTCTTTAGMMAD010
Pat 3 in DC3p.C19fsX20c.57_64delCTCTTTAGp.C19fsX20c.57_64delCTCTTTAGMMAD003
referenceexonallele 2allele 1phenotypepatient
 
Table 1 lists patient number, clinical phenotype, the mutations found on the two alleles as well as the affected 
exon/intron and the reference in which the patient was first published. 
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Figure 1: Ado- and MeCbl synthesis after expression of the empty vector, the vector carrying the wildtype 
MMADHC and the vector in which the putative endogenous mitochondrial leader sequence (MLS) of 
MMADHC was replaced with the potent MLS of aldehyde dehydrogenase 2 (ALDH2), in immortalized cblD-
MMA/HC fibroblasts (D007). 
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Figure 2: Mitochondrial AdoCbl synthesis after expression of the empty vector, the vector carrying the 
wildtype MMADHC and the vector in which the putative endogenous mitochondrial leader sequence 
(MLS) of MMADHC was replaced with the potent MLS of aldehyde dehydrogenase 2 (ALDH2), in various 
immortalized cblD-MMA and control fibroblasts. 
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Figure 3: MMADHC mRNA levels in various cblD patients. mRNA levels were normalized to levels of 
GAPDH mRNA. 
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Figure 4: Effect on mitochondrial AdoCbl synthesis after co-expression of the vector in which the putative 
endogenous mitochondrial leader sequence (MLS) of MMADHC was replaced with the potent MLS of 
aldehyde dehydrogenase 2 (ALDH2), together with the empty and the wildtype vector as well as with 
vectors carrying mutations associated with cblD-MMA and one associated with cblD-MMA/HC in 
immortalized cblD-MMA/HC fibroblasts (D007). 
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Figure 5: Effect of MeCbl (5a, left) and AdoCbl (5b, right) synthesis after expression of empty vector as 
well as the vectors carrying the indicated MMADHC constructs in immortalized cblD-MMA/HC fibroblasts 
(D007).
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pTracer effect on protein expected size(s)
1. vector only -
2. wild-type 32.8 kDa 26.5 kDa
3. c.57-64del p.C19fsX20 26.5 kDa
4. c.419dupA p.Y140X 15.1 kDa 8.6 kDa
5. c.748C>T p.R250X 27.8 kDa 21.4 kDa
6. c.696+1_4delGTGA p.F204_A232del 29.8 kDa 23.3 kDa
7. c.683C>G p.S228X 25.3 kDa 18.8 kDa
8. no DNA -
1 2 3 4 5 6 7 8
37 kDa
20 kDa
25 kDa
15 kDa
 
Figure 6: In vitro transcription translation using various pTracer constructs as templates. 
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Supplementary figure 1: Expression of wildtype and Mutant Alleles of MMADHC cblD-MMA/HC fibroblasts 
(D007). 
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Supplementary figure 2: Expression of wildtype MMADHC in various cblD-MMA fibroblasts (D003, D010) 
using various expression vectors. 
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Supplementary figure 3: Expression of wildtype and mutant MMADHC alleles associated with the cblD-
MMA phenotype into cblD-HC (D002) and control fibroblasts. Effect on synthesis of adenosyl- and 
methylcobalamin (AdoCbl and MeCbl) synthesis. 
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Supplementary table 1: Sequences of all primers used in the study. 
ttcattcacatattatgccatcacaaactcatgtctttcacttgMMADHC Q118XcblD_SDM_Q118X_r
gttgtttgtgatggcataatatgtgaatgaatttcagggtaatgatgMMADHC Q118XcblD_SDM_Q118X_f
ggcttttcttctgttaagcagtcccattgaggtgacaatcMMACHC S89XcblD_SDM_S89X_r
ctcaatgggactgcttaacagaagaaaagcctggttcMMACHC S89XcblD_SDM_S89X_f
ctgaaattcattcacatattgtgcctgcacaaactcatgMMADHC M116QcblD_3ATG_CAG_r
gtgaaagacatgagtttgtgcaggcacaatatgtgMMADHC M116QcblD_3ATG_CAG_f
ccaaagggtccctgagtttcatcaggccacactgttcMMADHC M62QcblD_2ATG_CAG_r
ggcctgatgaaactcagggaccctttggacctcaagMMADHC M62QcblD_2ATG_CAG_f
acatagaattcaagtgaaagacatgatruncating MMADHCCblD_3ATG_EcoRI_f
acatagaattctgatgaaactatgggatruncating MMADHCCblD_2ATG_EcoRI_f
gcctgggccgccgcctcttgtcagccgccgccacccaggccatggcacaatatgtgaatgadding MLS of ALDH2ALDH_CblD_in_Met116_f
gcctgggccgccgcctcttgtcagccgccgccacccaggccatgggaccctttggacctcadding MLS of ALDH2ALDH_CblD_in_Met62_f
gcctgggccgccgcctcttgtcagccgccgccacccaggccgtttcctatctcccaggatadding MLS of ALDH2ALDH_CblD_in_Val12_f
gcctgggccgccgcctcttgtcagccgccgccacccaggccatggccaatgtgctttgtaadding MLS of ALDH2ALDH_CblD_in_Met1_f
ccgctgcgatgttgcgcgctgccgcccgcttcgggccccgcctgggccgccgcctcttgtadding MLS of ALDH2ALDH_CblD_out_f
ctatggcgcgccctattaatgatgatgatgatgatgggctaaatttccacttaatttcttcat6x HIS tagging (clone into pcDNA3.2/V5)cblD_AscI_6His_r
agataggcgcgccaaatgaatggatatttctgcttatttccV5-tagging (clone into pcDNA3.2/V5)cblD_AscI_V5_r
acatagcggccgcccttgttctgggacagcV5- and His -tagging (clone into pcDNA3.2/V5)cblD_NotI_pcDNA_f
ccaataaccctcagctcgaasequencing MMADHC constructs820R
gaaagtgccagagtagagtgsequencing MMADHC constructs581F
caatgtggatgtgttcaacgfull-length MMADHC1260R
gttctgggacagctggagacfull-length MMADHC72F
sequence (5' - 3')purposeprimer
 
Restriction sites are underlined. Mutated triplets are depicted in red. His-tag and MLS ALDH2 are in blue. 
Overlapping part of outer ALDH2 primer (ALDH_CblD_out_f) is in italics. Bold triplets indicate first triplet of 
MMADHC. 
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OUTLOOK AND CONCLUDING REMARKS 
MCC related work 
MCC deficiency is increasingly questioned to be a disease as such. Our data provide strong 
indications that factors other than the genotype at the MCC loci, such as modifying genes 
and environmental factors, must have a major influence on the phenotype of MCC deficiency 
(156). In that respect, MCC deficiency is a good example of the now generally accepted idea 
of complexity in monogenic traits (65). 
There are however still numerous MCC-related research projects that could be of interest, 
they include: 
1: The dominant negative mutation found in MCCA (p.R385S) leads to a very stable, but 
non-functional protein (159) To date, our metabolic laboratories in Zurich and Basel have 
received more than 20 patient cell lines with suspected MCC deficiency, which have MCC 
activity at or just below the lower normal range associated with a reduced MCC/PCC ratio. 
Analysis of 2 such patients revealed the MCCA p.R385S mutation on one allele. It is possible 
that also some of the other subjects in this group carry other mutations with a similar effect. 
2: Another interesting mutation is the MCCB p.224L mutation found in exon 7 of MCCB. This 
exon is spliced out to some extent in all patient and control cells tested so far, raising the 
question of the importance of exon 7. As exon 7 is in-frame, the deletion of this exon leads to 
a shorter protein with the same N- and C-terminus as the wild type protein. We have shown 
that constructs missing exon 7 do not show any rescue of MCC activity when transfected into 
MCC deficient fibroblasts, nor is any stable protein produced from this construct. It would be 
interesting to see if this is the case in cells other than fibroblasts as this shorter protein might 
have some other tissue-specific function. 
3: The missense mutation MCCA p.M325R was found in exon 10 of a compound 
heterozygous patient along with another missense mutation MCCA p.A289V in exon 8. 
Analysis of this region of MCCA by RT-PCR resulted in 2 transcripts differing in size by 
128 bp. Direct sequencing of the 2 products revealed that the transcript of normal length 
contained the missense mutation in exon 8, while the shorter transcript led to skipping of 
exon 10 and coded for a normal exon 8. We were able to detect the exon 10 missense 
mutation p.M325R only by direct sequencing of amplified genomic DNA. We hypothesize that 
the mutation in exon 10 causes exon skipping because of disruption of an exon splice 
enhancer sequence (ESE) as it has been shown for the MCCB G352R mutation (263). 
 
Finally, research on MCC can serve as an example for other biotinylated enzymes and their 
disorders. Also the MCC genes can be utilized as model genes for analyzing the effect of 
various mutations found in our subjects. 
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Cobalamin related work 
Many genes responsible for the different complementation groups of cobalamin metabolism 
have been described, however, the exact location and function of most of them is still 
unknown. By describing the dual localization of MMADHC we have shed some light on 
intracellular cobalamin metabolism. There are still numerous open questions regarding the 
state of cobalamin after each of the intracellular steps, also the question regarding complex 
formation or interaction with other proteins of the various proteins involved in intracellular 
cobalamin metabolism remain unanswered. Interaction partners could possibly be found by 
using pull-down assays or a yeast-two-hybrid system. 
Patients with defects in cobalamin uptake for example should also present with 
homocystinuria, however publications on these defects do not mention elevated levels of 
homocysteine. Some case reports of patients with TCII deficiency reported normal levels of 
plasma homocysteine and amino acid (226). This raises the question on alternative ways of 
import of cobalamin into cells. This question needs to be addressed in future experiments. 
The MMADHC protein has been a nice tool to investigate a protein that serves two functions 
in two distinct compartments of the cell. Also the balance of localization that could be altered 
in one or the other way by cleaving and enhancing the MLS has been nice to study. In this 
respect MMADHC can be a research tool for other proteins with similar distribution patterns 
and functions. The data presented in chapter 3 of this thesis could not be supported by 
protein data so far as no antibody was available. A custom made monoclonal antibody is now 
being tested and will be used to investigate the theory of reinitiation of translation in protein 
extracts of control and patient fibroblasts as well as in TNT assays. As a recent paper reports 
that MMADHC could also serve as an adaptor protein for the complexation of MMACHC to 
acceptor proteins in the cytoplasm and in mitochondria (227), this antibody will be a helpful 
tool for identifying binding partners of MMADHC.  
 
As a concluding word, I would like to mention that research on rare metabolic disease is 
important and that a lack of knowledge about these disorders can not only have severe 
consequences for the subject itself but also on the parents or caretakers as the following 
(and quite recent) example illustrates: 
In 1989 a US woman was sentenced to life in prison after her son had died by suspected 
ethyleneglycol poisoning, an ingredient of antifreeze. During her time in prison, she gave 
birth to a second child that was also acutely ill, clinical investigation of the second child 
revealed high levels of methylmalonic acid. When re-analyzing the sample of the first child, 
the same finding was made. Methylmalonic acid had been mistaken for ethyleneglycol. In 
fact, both the first and the second child actually suffered from methylmalonic aciduria (264). 
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